

## **CURRICULUM VITAE**

Professor Sir Jonathan Stafford **Nguyen-Van-Tam**  
MBE (Military Division), BMedSci, BM BS, DM,  
FFPH, FRCPath, FRSPH, FRSB, FMedSci, DUniv *h.c.*, DSc *h.c.*,  
Hon FFPM, Hon FRCP

### **Pro Vice-Chancellor**

Faculty of Medicine and Health Sciences,  
University of Nottingham, UK

Formerly, **Deputy Chief Medical Officer**  
Department of Health and Social Care, England

## **SHORT BIOGRAPHY**

Jonathan Van-Tam (JVT) graduated in Medicine from the University of Nottingham in 1987. After 5 years of hospital-based clinical medicine, he pursued an academic training in public health and epidemiology with a special interest in influenza and respiratory viruses. He became a Senior Lecturer (Associate Professor) at the University of Nottingham (and Consultant Regional Epidemiologist, Public Health Laboratory Service) in 1997, before joining the pharmaceutical industry as an Associate Director (Anti-Infectives, New Product Development) at SmithKline Beecham in 2000. After a move to Roche as Head of Medical Affairs (UK) where he launched oseltamivir (Tamiflu®), he joined Aventis Pasteur MSD as UK Medical Director, with clinical responsibility for its large vaccine portfolio.

He returned to the public sector in 2004 at the Health Protection Agency Centre for Infections (Colindale), where he was Head of the Pandemic Influenza Office until October 2007. JVT then returned to Nottingham as Professor of Health Protection, maintaining his 25-year special interest in influenza and other respiratory viruses: epidemiology; transmission; vaccinology; antiviral drugs; and pandemic preparedness. He has published over 200 peer-reviewed scientific papers (generating over 16,000 citations) and written multiple chapters in textbooks. His h- & i10-indices are respectively 62 and 157.

He chaired the European Centre for Disease Prevention and Control (ECDC) Expert Advisory Group on H5N1 vaccines, and was a member of the UK national Scientific Pandemic Influenza Committee (SPI) from 2005 to 2009.

He was a member of the UK Scientific Advisory Group for Emergencies (SAGE) during the 2009-10 A/H1N1 influenza pandemic, and has acted as a short-term consultant and temporary adviser to the World Health Organization (WHO), ECDC, and the European Commission (EC) on multiple occasions since 2005.

He is Senior Editor of the highly rated textbook: “Introduction to Pandemic Influenza” which he published 09 in November 2009, with a Second Edition following in December 2013; and from 2014-2017 was Editor-in-Chief of Influenza and Other Respiratory Viruses (John Wiley & Sons Inc.).

In late 2014 he became Chair of the UK’s New and Emerging Respiratory Virus Threat Advisory Group (NERVTAG): the Department of Health’s senior scientific and clinical advisory committee for pandemic influenza and other emerging respiratory virus threats. He ran a WHO official Collaborating Centre for pandemic influenza at Nottingham University from 2010-2017.

From late 2017 he has been seconded to the Department of Health and Social Care, England as Deputy Chief Medical Officer where his portfolio is vaccines, pharmaceuticals, health protection, and biosecurity. In that role he has been extensively involved in domestic vaccines policy, seasonal influenza, infectious disease incidents (Ebola, Monkey Pox), the Novichok attack, and the Covid-19 pandemic, including every aspect of the successful UK vaccine procurement and deployment programme. He is a member of the UK Scientific Advisory Group for Emergencies (SAGE) and c-Chair of the Global Health Security Advisory Group (GHSAG) pandemic influenza working group (PIWG). He was awarded a Knighthood for services to Public Health in 2022.

He is scheduled to return to the University of Nottingham in 2022.

### **KEY SKILL SETS**

- Medically trained Epidemiologist/Public Health Physician. Accreditation in Public Health Medicine.
- Clinical background in Acute and Emergency Medicine, Anaesthesia, and Infectious Diseases
- Consultant-level experience in Health Protection (Communicable Disease Control)
- Two separate periods of senior academic experience at the University of Nottingham School of Medicine
- Globally recognised expert on: respiratory virus infections, influenza epidemiology; vaccines; neuraminidase inhibitors; pandemic preparedness and response; influenza transmission and infection control.
- Broad-ranging UK pharmaceutical and vaccines industry experience, progressing rapidly to Head of Medical Affairs (Roche) and then UK Medical Director of Aventis-Pasteur MSD.
- Intensive experience in medical marketing and new product development and market access for antibiotics, antiviral drugs, and vaccines.
- Very senior experience in UK government as Deputy Chief Medical Officer.
- Member and Chair of multiple UK and international scientific advisory committees including the Scientific Advisory Group for Emergencies (SAGE) during the 2009-10 influenza pandemic, SAGE 2019-2021.
- Familiar with the organisational culture, practices and policies of the UK National Health Service (NHS England); UK universities; Public Health England (PHE); pharmaceutical and vaccines industries; academia; the UK Government; Medicines and Healthcare products Regulatory Agency (MHRA); European Centre for Disease Control and Prevention (ECDC); European Commission (DG Santé); Global Health Security Advisory Group (GHSAG); and the World Health Organization (WHO).
- Strong working relationships with many senior health officials across Europe and the US Centers for Disease Control and Prevention (CDC) and Health and Human Services (HHS)
- Extensive and far-reaching international network of contacts in field of respiratory virus infections and influenza, spanning academia, clinical services, public health authorities, governments and the pharmaceutical and vaccines industries.
- Significant corporate and commercial managerial experience. Experienced in person management and very senior leadership roles. Significant political skills and experience.
- Excellent communicator and teacher; sought after speaker/lecturer; trained and very experienced in all forms of media work. French to level B1/B2 (intermediate).
- Dual British and EU citizenship.

**PERSONAL**

**Name** NGUYEN-VAN-TAM, Jonathan Stafford

**Address** GRO-C  
Lincolnshire  
GRO-C

**Telephone** +44: GRO-C (mobile)  
+44: GRO-C (desk)

**E-mail** [vt@](mailto:vt@) GRO-C

**Date of birth** GRO-C 1964

**Place of birth** GRO-C England

**Nationality** Dual British/French

**Ethnic origin** mixed Vietnamese/British

**Marital status** GRO-C

**EDUCATION**

1975-1982 Boston Grammar School, Lincolnshire

1982-1987 University of Nottingham, School of Medicine

**ACADEMIC QUALIFICATIONS**

1985 Bachelor of Medical Sciences (2nd Class Honours, upper division)

1987 Bachelor of Medicine, Bachelor of Surgery

1995 Diploma of Membership of the Faculty of Public Health Medicine of the Royal Colleges of Physicians, United Kingdom (MFPHM)

2001 Doctor of Medicine (Division of Epidemiology & Public Health), University of Nottingham (DM)

## **FELLOWSHIPS, AWARDS, AND PRIZES SINCE 1987**

1997	Member of the Most Excellent Order of the British Empire (MBE), Military Division
2006	Awarded Fellowship of the Faculty of Public Health of the Royal College of Physicians, UK (FFPH)
2007	Elected to Fellowship of Royal Society of Public Health (FRSPH)
2013	Elected to Fellowship of the Royal Society of Biology (FRSB)
2014	Awarded Fellowship of Royal College of Pathologists, UK (FRCPath)
2015	Awarded Honorary Fellowship of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, UK (Hon FFPM)
2021	Communiqué Awards: Healthcare Communications Advocate of the year
2021	Awarded Honorary Fellowship of the Royal College of Physicians, England (Hon FRCP)
2021	Elected to Fellowship of the UK Academy of Medical Sciences (FMedSci)
2021	Freedom of the Borough of Boston, Lincolnshire
2021	Doctor of the University, <i>honoris causa</i> , Bishop Grosseteste University, Lincoln (DUniv)
2021	Doctor of Science, <i>honoris causa</i> , University of Lincoln (DSc)
<b>2022*</b>	<b>Knight Bachelor (Kt), for services to Public Health</b>
2022*	Doctor of Laws, <i>honoris causa</i> , University of Nottingham
2022*	Toastmasters International, Communication and Leadership Award
2022*	Awarded Honorary Fellowship of the Faculty of Public Health for distinguished contribution to Public Health
2022*	Awarded Honorary Fellowship of the Royal Society for Public Health
2022*	Royal Society for Public Health Award for outstanding contribution to Public Health

\*(awarded but ceremonies pending)

## **EARLY CAREER**

University Hospital, Nottingham	House Officer in General Medicine and Dermatology	August 1987 - January 1988
Grantham and Kesteven Hospital	House Officer in General Surgery	February 1988 - July 1988
University Hospital, Nottingham	Senior House Officer in Accident and Emergency	August 1988 - January 1989
City Hospital, Nottingham	Senior House Officer in Geriatric Medicine	February 1989 - July 1989
University and City Hospitals, Nottingham and Lincoln County Hospital	Senior House Officer rotation in Anaesthesia	August 1989 - July 1990
Infectious Diseases Unit, Groby Road Hospital/ Leicestershire Health Authority	SHO Infectious Diseases/Communicable Disease Control	August 1990 - January 1991
Leicester Royal Infirmary	SHO General Medicine and Diabetology	February 1991 - July 1991
University of Leicester Department of Community Health	SHO Academic Public Health Medicine	August 1991* (*terminated by promotion)
University of Nottingham	Clinical Lecturer in Public Health Medicine and Epidemiology	September 1991 - October 1997
University of Nottingham	Clinical Senior Lecturer in Public Health Medicine and Epidemiology	October 1997 - December 1999

**PHARMACEUTICAL and VACCINE INDUSTRY APPOINTMENTS****SmithKline Beecham****Associate Director (Anti-infectives)  
Clinical Development & Medical Affairs****January 2000-  
March 2001**

Experience gained within SB post:

- Opinion Leader liaison
- Appraisal of potential investigators
- Clinical trial design, implementation and support
- Market access/market understanding
- Development of Brand Essence/Brand Story
- Market development and New Product Introduction (NPI) activities
- Association of the British Pharmaceutical Industry (ABPI) Code of Practice, Copy Approval Process
- Prescription Medicines Code of Practice Authority (PMCPA) complaints procedures (incoming and outgoing)
- Support to Product Safety, Medical Information, and Regulatory Affairs departments
- Sales Force training
- Design of promotional materials
- Design of Sales Force distance learning training materials
- Cross-functional working within Market Aligned Planning (MAP) teams
- Cross-functional working and organisational change (UK Merger Integration Team)
- External committee attendance (ABPI Working Groups and PHLS Advisory Committees)
- Liaison with European colleagues in Therapy Area Team (TAT) and Global Marketing Group (GMG)

**Roche Products Ltd.**

**Head of Medical Affairs  
(Specialty Products)**

**April 2001 -  
February 2002**

- Day-day person and team management/team building
- Undertaking individual performance reviews and appraisals against objectives (PDP)
- Budgetary management
- Human Resources (HR) procedures, including recruitment and disciplinary processes
- Membership of European Product Launch Teams
- Regular deputising for Medical Director
- Formulation of NICE submissions and dealing with NICE appeals process
- Formal HR training for managers

**Aventis Pasteur MSD**

**Medical Director**

**February 2002  
- July 2004**

- Vaccine development and licensure
- Working at UK Company Director level; exposure to full range of corporate-level issues
- Membership of European Management Group; membership of European Medical Management Team
- Membership of Influenza Strategic Group (Europe)
- Emergency batch-recall procedures
- Parliamentary lobbying and face-face interaction with Members of Parliament and Government Ministers
- Member of International Federation Pharmaceutical Manufacturers Associations Influenza Vaccine Supply Task Force (Policy and Public Affairs sub-group)
- Understanding of production, supply and logistic issues
- Establishment of distinct Medical Affairs function; reorganisation of Vaccine Information Services
- Success in securing countrywide age-based recommendation for pneumococcal polysaccharide vaccination for elderly persons
- Successful adoption of new IPV-containing vaccines into UK childhood schedule

## **RETURN to PUBLIC SECTOR from 2004 onwards**

**Consultant Epidemiologist  
Health Protection Agency  
Centre for Infections**

**July 2004 – October 2007**

(included: Head, Pandemic Influenza Office

October 2005 – October 2007)

In the role of Consultant Epidemiologist, I held national responsibility within the HPA for:

- Operational response to incidents and outbreaks of respiratory virus infection
- Advice on use of vaccines and antiviral drugs against influenza and RSV
- Epidemiological/Public Health R&D for influenza and respiratory viruses

I jointly managed routine surveillance activities for influenza and other respiratory viruses as well as sharing in the daytime and out-of-hours commitments of the national communicable disease control on-call service provided by the Centre for Infections.

I was the Agency's Respiratory Research and Development Theme Leader, and retained this responsibility until the HPA's dissolution in 2013. This involved providing strategic leadership and direction to the Agency's R&D programme for respiratory infections.

In the role of Head of the Pandemic Influenza Office (established in autumn 2005) I formed and built a new unit with lead responsibility for:

- Coordination of pandemic preparedness activities within the HPA
- Liaison with government departments regarding expert advice on pandemic preparedness
- Synthesis, collation and preparation of expert scientific advisory documents to central government, to inform policy making on pandemic response

I played a prominent leadership role in national pandemic preparedness activities within the HPA and in liaison with multiple government departments from 2004 until late 2007. The role also gave me significant international involvement in pandemic planning for the European Union, European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO).

**Professor of Health Protection**  
**Division of Epidemiology and Public Health**  
**School of Medicine**  
**University of Nottingham**

**October 2007 – March 2022**

I was appointed as Foundation Clinical Professor in Health Protection in October 2007. The post was a new venture, funded by the HPA and thereafter Public Health England.

Key achievements to date:

- Expansion of unit size from 'sole practitioner', single-handed status, to approx 15.0 WTE staff and PhD students (by 2013)
- > £24M in research funding since 2007
- Funding from: MRC; Wellcome Trust; NIHR; HPA; DH (England); US CDC, EU (FP7) and industry
- 2008: MRC Clinical Research Fellowship
- 2010: ESRC/MRC Interdisciplinary PhD Studentship
- 2010: WHO PhD Studentship
- 2010: WHO Collaborating Centre for pandemic influenza and research, twice renewed
- 2010-2019: Faculty of Public Health 'National Treasure' training location
- 2011-2017: PHE Field Epidemiology Training Programme location
- Seconded from 2017 onwards to Department of Health and Social Care, England as Deputy Chief Medical Officer

**Deputy Chief Medical Officer  
Department of Health and Social Care  
(DHSC) England**

**October 2017 – March 2022**

Seconded to a senior UK Government role for an initial period of 2 years, but extended until September 2022 (3-month notice period). Providing strategic medical leadership and policy advice to Her Majesty's Government on Public Health, but specifically health protection: communicable disease control, vaccination, seasonal and pandemic influenza preparedness, CBRN threats, biosecurity, and antimicrobial resistance. Senior Leadership role during SARS-CoV-2 pandemic 2020 to 2022.

Key roles in post:

- Conversion of UK influenza vaccine policy to adjuvanted vaccines for the elderly, and quadrivalent non-egg formulations throughout.
- Leadership on Ebola DRC and west African Monkey Pox incidents
- Public health advice during Novichok attacks, Salisbury
- Covid-19 pandemic response
- Co-ordination of activities for Joint Committee on Vaccination and Immunisation (JCVI); oversight of UK vaccine programme
- Almost daily interactions with Health Ministers
- Very frequent interaction with No.10 Downing Street and the UK Prime Minister
- Clinical Adviser UK Covid-19 Vaccines Task Force
- Clinical Adviser UK Covid-19 Therapeutics and Antivirals Task Forces
- Member UK Scientific Advisory Group for Emergencies (SAGE), Covid-19
- Very high-profile public communications
- Co-Chair Global Health Security Advisory Group (GHSAG), pandemic influenza working group (PWIG)
- Member, WHO Working Group on Influenza Preparedness and Response

## **CURRENT APPOINTMENTS**

**Pro Vice-Chancellor  
Faculty of Medicine & Health Sciences  
University of Nottingham**

**May 2022 -**

A senior leadership role, upon my return from DHSC. Responsible for strategic leadership of four major Schools in the university: Medicine, Health Sciences, Life Sciences and Veterinary Medicine & Science.

**Non-Executive Director  
NHS Lincolnshire Integrated Care Board**

**May 2022 -**

A senior advisory and challenge role within the newly formed Integrated Care Structures in Lincolnshire (and nationally).

## **HONORARY APPOINTMENTS**

Nottingham Health Authority	Honorary Registrar in Public Health Medicine	September 1991 - August 1993
North Lincolnshire Health Authority	Honorary Senior Registrar in Public Health Medicine	September 1993 - March 1994
Lincolnshire Health	Honorary Senior Registrar in Public Health Medicine	April 1994 - September 1995
Nottingham Health	Honorary Senior Registrar in Public Health Medicine (Communicable Disease Control)	October 1995 - June 1997
Queens Medical Centre NHS Trust, Nottingham	Clinical Assistant in Accident & Emergency	April 1995 - July 1997
Public Health Laboratory Service, Communicable Disease Surveillance Centre, Trent	Honorary Consultant Regional Epidemiologist	November 1997 - December 1999
Health Protection Agency East Midlands	Honorary Consultant Regional Epidemiologist	October 2007 - March 2013
Public Health England	Honorary Consultant Epidemiologist and Head of Research & Development, Field Epidemiology Service	April 2013 – September 2017

## **SPECIALIST REGISTRATION**

I am registered with the General Medical Council as a Specialist in Public Health Medicine. I gained full accreditation in Public Health Medicine on 01.09.96 (JCHMT code 03235L), and was awarded the Certificate of Completion of Specialist Training (CCST) on 10.03.97.

## **NATIONAL AND INTERNATIONAL RECOGNITION**

### **Key invited lectures and presentations in plenary sessions etc.**

I receive numerous requests to deliver lectures and presentations on influenza pandemic preparedness in the UK, to diverse groups ranging from international banking societies, to security and business continuity professionals, as well as Plenary Lectures at medical and scientific symposia. I believe this testifies to my reputation as a speaker/teacher and my ability to communicate effectively with audiences with from diverse backgrounds and with different levels of technical knowledge. I do not record all of these on my CV as they are too great in number.

2021	Royal College of Physicians, Harveian Orator 2021
2021	Royal Institution, Christmas Lecturer 2021
2022	Wade Lecture, University of Southampton
2022*	Royal College of Pathologists, Diamond Jubilee Lecture
2022*	Thomas Francis Jnr Memorial Lecture, University of Michigan

*\*(scheduled, but not yet delivered)*

### **Journal Referee/Editorial Boards/Editorships**

I referee papers for *Journal of Public Health Medicine, Public Health, Journal of Epidemiology and Community Health, Vaccine, British Medical Journal, Lancet, Vaccine, European Respiratory Journal, Journal of Medical Microbiology, Archives of Disease in Childhood, Journal of Antimicrobial Chemotherapy, Journal of Infection, Epidemiology and Infection, Clinical Infectious Diseases, Journal of Infectious Diseases, and several other journals.*

I was a Senior Editor of Influenza and other respiratory viruses ([www.influenzajournal.com](http://www.influenzajournal.com)) from 2008 and became its Editor-in-Chief in early 2014 until September 2017.

### **Formal consultancies and membership of national and international committees**

1. Member: Health Protection Agency (formerly Public Health Laboratory Service) Respiratory viruses - Influenza Forum, 1998 - 2003
2. Member: Public Health Laboratory Service (PHLS) Advisory Committee (SAC) on Systemic and Respiratory Infections, 1999
4. Member: Association of British Pharmaceutical Industry Working Group on Antimicrobial Resistance, 2000 – 2004
5. Member: Secretary of State for Health's Specialist Advisory Committee on Antimicrobial Resistance (SACAR), 2001-2004.
6. Regular lecturer at Home Office Emergency Planning College on Pandemic Planning for influenza, 1998-2003.
7. Member: European Federation of Pharmaceutical Industry Associations (EFPIA), Influenza Vaccine Supply (IVS) Task Force, 2002-2004.
8. Temporary Adviser: World Health Organization Global Influenza Programme, Geneva, December 2004 – present
9. Temporary Expert Advisor/Facilitator: EU Commission (DG Santé), Luxembourg, March 2005 - 2020
10. Member: Joint Committee on Vaccination and Immunisation: RSV sub-group, 2004 – 2007.
11. Member: Health Protection Agency Influenza and Respiratory Virus Programme Board, 2004 – 2013
12. Member: European Centre for Disease Prevention and Control (ECDC) Expert Advisory Committee on Pandemic Influenza, Jan 2006 – 2007
13. Member: ECDC Inspection/Assessment Team for Member State Pandemic Preparedness, Nov 2006 (Czech Republic).
14. Chair: ECDC Expert Advisory Group on human H5N1 vaccines, January – September 2007.

15. Member: Royal Society delegation to South Korea, to discuss pandemic influenza vaccines, March 2007.
16. Consultant: World Health Organization, Regional Office for Europe: November 2007 - 2020
17. Member: UK Scientific Pandemic Influenza Advisory Committee (and predecessor committee), 2005 – 2009
18. Member: UK Scientific Advisory Group for Emergencies (SAGE), April 2009 – Summer 2010
19. Expert Advisor and Spokesperson: Swiss Government H1N1 (swine flu) vaccination programme evaluation, 2010 - 2011.
20. National Institute for Health Research (NIHR), Pandemic Research Assessment Panel, 2011 – present.
21. National Institute for Health Research (NIHR), College of Experts: Respiratory Infections, 2013 – present.
22. Chair: UK NERVTAG (New and Emerging Respiratory Virus Threat Advisory Group), Department of Health. Late 2014 – September 2017.
23. Co-Chair: GHSAG Pandemic Influenza Working Group (PIWG), December 2017 – present.
24. Member: WHO Working Group on Influenza Preparedness and Response, 2018 – present.
25. Clinical Adviser: UK Covid-19 Vaccines Task Force, April 2020 – present.
26. Clinical Adviser: UK Covid-19 Therapeutics and Antivirals Task Forces, April 2020 – present.
27. Member: UK Covid-19 Scientific Advisory Group for Emergencies (SAGE) February 2020 – present.

### **Other wider public health roles**

1. Faculty of Public Health Appointments Advisory Committee Assessor 2008 – 2017.
2. Faculty of Public Health, Deputy Faculty Adviser, 2010 – 2015.
3. Public Health England, GMC Revalidation Appraiser East Midlands and National 2013 – 2017.
4. Faculty of Public Health, Academic and Educational Supervisor (HEE London), 2020 - 2022
5. NHS Covid-19 Vaccinator (Lincolnshire and Nottinghamshire), 2021 - 2022

## **POSTGRADUATE STUDIES**

### **Higher degrees**

In July 2001, I was awarded the degree of Doctor of Medicine. My thesis described work on influenza epidemiology and influenza vaccination policies, undertaken during the 1990s.

### **Continuing Professional Development (CPD) since accreditation**

I have participated in the UK Faculty of Public Health CPD scheme since 1997. In April 2015, having been awarded FRCPath, I decided to switch to the Royal College of Pathologists CPD scheme where I am now registered and remain in good standing with both colleges.

### **Management Training and Personality Attributes**

I was selected for the HPA Senior Management Development Programme, 2006-07. At a Development/Assessment Centre I was formally assessed against the Agency's six leadership qualities (on a scale of 'strong', through 'competent' to 'requires development'). I was judged to be strong in 'Drive for Results' and 'Collaborative Working'.

Using Saville-Wave psychometric tests for professional style, I was rated as 'extremely high' for 'Providing Leadership' and 'Achieving Success' and 'high' for 'Presenting Information'.

In terms of Myers-Briggs personality scores I rate as: 'type ESTJ'

- **Mildly extrovert** (gain your energy from people and things in the world around you, rather than from internal things)
- **Moderate for sensing** (pay attention to what your experience and what your senses tell you, rather than what your personal intuition says)
- **Very strong for thinking** (decide by using thinking, logic and the facts, rather than feelings)
- **Very strong for judging** (being organised and having a plan of action)

## **PEER-REVIEWED ARTICLES DESCRIBING ORIGINAL RESEARCH**

1. **Nguyen-Van-Tam JS**, Pearson JCG.  
Adolescent desires and beliefs about motorcycling: implications for education.  
*Health Education Journal*, 1985; 44(3): 146-8.
2. **Nguyen-Van-Tam JS**, Pearson JCG.  
Teenagers and motorcycles: knowledge and perception of risks.  
*J Inst Health Education*, 1986; 24(1): 32-9.
3. Staff of the Accident and Emergency Departments of Derbyshire Royal Infirmary, Leicester Royal Infirmary and Queen's Medical Centre, Nottingham. Coping with the early stages of the M1 disaster.  
*Br Med J*, 1989; 289(6674): 651-4.  
(listed as **Van-Tam J**)
4. **Nguyen-Van-Tam JS**, Nicholson KG.  
Influenza deaths during the 1989-90 epidemic: implications for prevention.  
*Epidemiol Infect*, 1992; 108: 537-45.
5. **Nguyen-Van-Tam JS**, Baker DM.  
General practice and accident & emergency care: does the patient know best?  
*Br Med J*, 1992; 305(6846): 157-8.
6. **Nguyen-Van-Tam JS**, Nicholson KG.  
Influenza immunisation: policies and practices of general practitioners in England: 1991/92.  
*Health Trends*, 1993; 25(3): 101-5.
7. **Nguyen-Van-Tam JS**, Nicholson KG.  
Influenza immunisation: vaccine offer, request and uptake in high-risk patients during the 1991/92 season.  
*Epidemiol Infect*, 1993; 111: 347-55.
8. Baker DM, **Nguyen-Van-Tam JS**, Smith SJ.  
Protective efficacy of BCG vaccine against leprosy in southern Malawi.  
*Epidemiol Infect*, 1993 Aug; 111(1): 21-5.
9. Baker DM, Jones JA, **Nguyen-Van-Tam JS**, Lloyd JH, Morris DL, Bourke JB, Steele RJC, Hardcastle JD.  
Taurolidine peritoneal lavage as prophylaxis against infection after elective colorectal surgery.  
*Br J Surg*, 1994; 81: 1054-6.
10. Lee FI, **Nguyen-Van-Tam JS**.  
Prospective incidence of Crohn's disease in north-west England: no increase since the late 1970's.  
*Eur J Gastroenterol*, 1994; 6(1): 27-31.
11. Ahmed AH, Nicholson KG, **Nguyen-Van-Tam JS**.  
Reduction in mortality associated with influenza vaccine during the 1989/90 epidemic: a case-control study.  
*Lancet*, 1995; 346: 591-5.
12. Warren SS, **Nguyen-Van-Tam JS**, Pearson JCG, Madeley RJ.  
Practices and policies for influenza immunisation in old people's homes in Nottingham during the 1992-93 season: potential for improvement.  
*J Public Health Med*, 1995; 17(4): 392-6.
13. **Nguyen-Van-Tam JS**, Madeley RJ.  
Do Cadet Force Units need a dedicated medical pack?  
*J R Army Med Corps*, 1995; 141: 83-6.

14. English WA, **Nguyen-Van-Tam JS**, Pearson JCG, Madeley RJ.  
Deficiencies in undergraduate and pre-registration medical training in prescribing for pain control.  
*Medical Teacher*, 1995; 17(2): 215-8.
15. **Nguyen-Van-Tam JS**, Simpson J, Madeley RJ, Davies L.  
Health care experiences of Vietnamese families in Nottingham.  
*Health Trends*, 1995; 27(4): 106-10.
16. Powar MP, **Nguyen-Van-Tam JS**, Pearson JCG, Dove AF.  
Hidden impact of paramedic interventions.  
*J Accid Emerg Med*, 1996; 13: 383-5.
17. Ahmed AH, Nicholson KG, **Nguyen-Van-Tam JS**, Pearson JCG.  
Effectiveness of influenza vaccine in reducing hospital admissions during the 1989-90 epidemic.  
*Epidemiol Infect*, 1997; 118(1): 27-33.
18. **Nguyen-Van-Tam JS**, Dove AF, Bradley MP, Pearson JCG, Durston P, Madeley RJ.  
Effectiveness of ambulance paramedics versus ambulance technicians in managing out-of-hospital cardiac arrest.  
*J Accid Emerg Med*, 1997; 14(3): 142-148.
19. Nicholson KG, **Nguyen-Van-Tam JS**, Ahmed AH, Wiselka MJ, Leese J, Ayres J, Campbell JH, Ebdon P, Eiser NM, Hutchcroft BJ, Pearson JCG, Willey RF, Wolstenholme RJ, Woodhead MA.  
Randomised placebo-controlled trial on effect of inactivated influenza vaccine on pulmonary function in patients with asthma.  
*Lancet*, 1998; 351(9099): 326-331.
20. Reaveley AM, **Nguyen-Van-Tam JS**, Logan RFA.  
Who dies from hernia?  
*J Epidemiol Comm Hlth*, 1998; 52: 532-533.
21. Bradley MP, **Nguyen-Van-Tam JS**, Pearson JCG.  
'Late presenters' after paracetamol self-poisoning.  
*J Epidemiol Comm Hlth*, 1998; 52: 762-763.
22. Kyaw MH, **Nguyen-Van-Tam JS**, Pearson JCG.  
Family doctor advice is the main determinant of pneumococcal vaccine uptake.  
*J Epidemiol Comm Hlth*, 1999; 53(9): 589-590.
23. **Nguyen-Van-Tam J**, Granfield R, Pearson J, Fleming D, Keating N.  
Do influenza epidemics affect patterns of sickness absence among British hospital staff?  
*Infect Control Hosp Epidemiol*, 1999; 20: 691-694.
24. Nguyen-Van-Tam SE, **Nguyen-Van-Tam JS**, Myint S, Pearson JCG.  
Risk factors for hospital acquired urinary tract infection in a large English teaching hospital: a case-control study.  
*Infection*, 1999; 27(3): 192-197.
25. Allen KW, **Nguyen-Van-Tam JS**, Howells J.  
Administration of time-expired yellow fever vaccine: public health response and results of a serological investigation.  
*Comm Dis Publ Health*, 1999; 2(2): 141-142.
26. Neal KR, **Nguyen-Van-Tam JS**, Monk P, O'Brien SJ, Stuart J, Ramsay M.  
Invasive meningococcal disease among university undergraduates: association with universities providing relatively large amounts of catered hall accommodation.  
*Epidemiol Infect*, 1999; 122: 351-357.

27. Neal KR, **Nguyen-Van-Tam JS**, White A, Jeffrey N, Madeley RJ, Job K, Wale MCJ, Ait-Tahar K, Slack RCB, Ala'Aldeen DAA.  
Seven-week interval between acquisition of a meningococcus and the onset of invasive disease.  
**Epidemiol Infect**, 1999; 123: 507-509.
28. Nabwera H, Logan RPH, **Nguyen-Van-Tam JS**, Logan RFA.  
Prevalence and risk factors for *Helicobacter pylori* (*Hp*) infection in Kenyan schoolchildren.  
**Gastroenterology** 1999; 116(4): A261.
29. Read CA, Mohsun A, **Nguyen-Van-Tam JS**, McKendrick M, Kudesia G.  
Outbreaks of influenza A in nursing homes in Sheffield during the 1997/98 season: implications for diagnosis and control.  
**J Public Health Med**, 2000; 22(1):116-120.
30. Neal KR, **Nguyen-Van-Tam JS**, Jeffrey N, Madeley RJ, Job K, Wale MCJ, Ait-Tahar K, Slack RCB, Ala'Aldeen DAA.  
Changing carriage rate of *Neisseria meningitidis* among university students during the first week of term: cross sectional study.  
**Br Med J**, 2000; 320: 846-849.
31. Nabwera HM, **Nguyen-Van-Tam JS**, Logan RFA, Logan RPH.  
Prevalence of *Helicobacter pylori* infection in Kenyan schoolchildren aged 3-15 years and risk factors for infection.  
**Eur J Gastroenterol Hepatol**, 2000; 12: 483-487.
32. Ala'Aldeen DAA, Neal KR, Ait-Tahar K, **Nguyen-Van-Tam JS**, English A, Falla TJ, Hawkey PM, Slack RCB.  
Dynamics of meningococcal long-term carriage among university students and their implications for mass vaccination  
**J Clin Microb**, 2000; 38(6): 2311-2316.
33. Tobin MD, **Nguyen-Van-Tam JS**, Bailey RC, Pearson JCG, Dove A, Durston P.  
Completeness of recording clinical information and diagnostic accuracy of ambulance crews using scanned patient report forms.  
**Pre-hospital Immediate Care**, 2000; 4: 143-147.
34. **Nguyen-Van-Tam JS**, Brockway CR, Pearson JCG, Hayward AJ, Fleming DM.  
Excess hospital admissions for pneumonia and influenza in persons over 65 years associated with influenza epidemics in three English health districts: 1987-1995.  
**Epidemiol Infect**, 2001; 126 (1): 71-79.
35. Hayman A, Moss T, Simmons G, Arnold C, Holmes EC, Naylor-Adamson L, Hawkeswell J, Allen K, Radford J, **Nguyen-Van-Tam JS**, Balfe P.  
Phylogenetic analysis of multiple heterosexual transmission events involving subtype B of HIV Type 1.  
**Aids Res Human Retro**, 2001; 17 (8): 689-695.
36. **Nguyen-Van-Tam JS**, Logan RFA Logan SAE, Mindell JS.  
What happens to medical students who complete an honours year in public health and epidemiology?  
**Medical Education**, 2001; 35:134-136.
37. Allen KW, Moss T, Evans BG, **Nguyen-Van-Tam JS**, Rogstad K, Radford J, Jewes L.  
Doncaster: the public health response to a local cluster of heterosexually acquired HIV infection.  
**Com Dis Publ Hlth**, 2002; 5(4): 271-275.
38. Marks PJ, Daniel TD, Afolabi O, Spiers G, **Nguyen-Van-Tam JS**.  
Emergency (999) calls to the ambulance service that do not result in the patient being transported to hospital: an epidemiological study.  
**Emerg Med J**, 2002; 19(5): 449-452.

39. Kumar A, Doran J, Batt ME, **Nguyen-Van-Tam JS**, Beckingham IJ.  
Results of inguinal canal repair in athletes with sports hernia.  
*J R Coll Surg Edinb*, 2002; 47(3): 561-565.
40. Da Silva PR, **Nguyen-Van-Tam JS**, Hayward AC.  
Logistic issues and potential prescribing costs associated with use of neuraminidase inhibitors for the treatment of influenza in primary care.  
*J Roy Soc Med*, 2003; 96: 66-69.
41. Enstone JE, Wale MCJ, **Nguyen-Van-Tam JS**, Pearson JCG.  
Adverse medical events in British service personnel following anthrax vaccination.  
*Vaccine*, 2003; 21: 1348-1354.
42. Hayward AC, Darton T, **Van-Tam JN**, Watson JM, Coker RJ, Schwoebel V.  
Epidemiology and control of tuberculosis in major western European cities.  
*Int J. Tuberc Lung Dis*, 2003; 7(8): 751-757.
43. MIV Study Group (listed as **J Nguyen-Van-Tam**).  
The macroepidemiology of influenza vaccination in 56 countries, 1997-2003.  
*Vaccine*, 2005; 23: 5133-43
44. Wallace LA, Young D, Brown A, Cameron JC, Ahmed S, Duff R, Carman WF, Kitchin NRE, **Nguyen-Van-Tam JS**, Goldberg DJ.  
Costs of running a universal adolescent hepatitis B immunisation programme.  
*Vaccine*, 2005; 23: 5624-31.
45. Goddard NL, Cooke MC, Gupta RK, **Nguyen-Van-Tam JS**.  
Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom.  
*Epidemiol Infect*, 2006; Jun 6: 1-4.
46. **Nguyen-Van-Tam JS**, Nair P, Acheson P, Baker A, Barker M, Bracebridge S, Croft J, Ellis J, Gellellie R, Gent N, Ibbottson S, Joseph C, Mahgoub H, Monk P, Reghitt TW, Sundkvist T, Sellwodd C, Simpson J, Smith J, Watson JM, Zambon M, Lightfoot N; Incident Response Team.  
Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis.  
*Euro Surveill*, 2006; 11(5): E060504.2
47. Muller D, **Nguyen-Van-Tam JS**, Szucs TD.  
Influenza vaccination coverage rates in the UK: A comparison of two monitoring methods during the 2002-03 and 2003-04 seasons.  
*Publ Hlth*, 2006; 120: 1074-80.
48. Gupta RK, Toby M, Bandopadhyay G, Cooke M, Gelb D, **Nguyen-Van-Tam JS**.  
Public understanding of pandemic influenza, United Kingdom.  
*Emerg Infect Dis*, 2006; 12(10).
49. Gupta RK, Zhao H, Cooke M, Harling R, Regan M, Bailey L, **Nguyen-Van-Tam JS**.  
Public health response to influenza in care homes: a questionnaire-based study of local Health Protection Units.  
*J Public Health*, 2007; 29(1): 88-90.
50. Phin NF, Rylands AJ, Allan J, Edwards C, Enstone JE, **Nguyen-Van-Tam JS**.  
Personal protective equipment in an influenza pandemic: a UK simulation exercise.  
*J Hosp Infect*. 2009 Jan;71(1):15-21.

51. Greatorex JS, Page RF, Curran MD, Digard P, Enstone JE, Wreghitt T, Powell PP, Sexton DW, Vivancos R, **Nguyen-Van-Tam JS**. Effectiveness of Common Household Cleaning Agents in Reducing the Viability of Human Influenza A/H1N1. *PLoS ONE*, 2010; 5(2): e8987. doi:10.1371/journal.pone.000898
52. Fleming DM, Verlander NQ, Elliot AJ, Zhao H, Gelb D, Jehring D, **Nguyen-Van-Tam JS**. An assessment of the effect of statin use on the incidence of acute respiratory infections in England during winters 1998-1999 to 2005-2006. *Epidemiol Infect*, 2010 Jan 29:1-8.
53. **Nguyen-Van-Tam JS**, Openshaw PJM, Hashim A, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Nicholson KG. Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). *Thorax*, 2010; 65: 645-651. doi:10.1136/thx/2010.135210
54. Pebody RG, Harris R, Kafatos G, Chamberland M, Campbell C, **Nguyen-Van-Tam JS**, McLean E, Andrews N, White PJ, Wynne-Evans E, Green J, Ellis J, Wreghitt T, Bracebridge S, Ihekweazu C, Oliver I, Smith G, Hawkins C, Salmon R, Smyth B, McMenamin J, Zambon M, Phin N, Watson JM. Use of Antiviral Drugs to Reduce Household Transmission of Pandemic (H1N1) 2009, United Kingdom. *Emerg Infect Dis*. 2011 Jun;17(6):990-9. PubMed PMID: 21749759.
55. Enstone JE, Myles PR, Openshaw PJ, Gadd EM, Lim WS, Semple MG, Read RC, Taylor BL, McMenamin J, Armstrong C, Bannister B, Nicholson KG, **Nguyen-Van-Tam JS**. Nosocomial pandemic (H1N1) 2009, United Kingdom, 2009-2010. *Emerg Infect Dis*. 2011 Apr;17(4):592-8. PubMed PMID: 21470446.
56. Bewick T, Myles P, Greenwood S, **Nguyen-Van-Tam JS**, Brett SJ, Semple MG, Openshaw PJ, Bannister B, Read RC, Taylor BL, McMenamin J, Enstone JE, Nicholson KG, Lim WS; Influenza Clinical Information Network. Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from inter-pandemic community-acquired pneumonia in adults. *Thorax*. 2011 Mar;66(3):247-52. Epub 2011 Jan 20. PubMed PMID: 21252388; PubMed Central PMCID: PMC3047189.
57. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina M, **Nguyen-Van-Tam JS**, Read RC, Warren FC, Zambon M. A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart. *Health Technol Assess*. 2010 Dec;14(55):193-334. PubMed PMID: 21208550.
58. Puleston RL, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson KG, **Nguyen-Van-Tam JS**. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. *Health Technol Assess*. 2010 Dec;14(55):1-82. PubMed PMID: 21208547.
59. Nicholson KG, Abrams KR, Batham S, Clark TW, Hoschler K, Lim WS, Medina MJ, **Nguyen-Van-Tam JS**, Read RC, Warren FC, Zambon M. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. *Lancet Infect Dis*. 2011 Feb;11(2):91-101. Epub 2010 Dec 16. PubMed PMID: 21168369.
60. Hashim AB, McKeever T, Kelly SJ, **Nguyen-Van-Tam JS**. Evaluation of inter-pandemic influenza vaccine effectiveness during eight consecutive winter seasons in England and Wales in patients with cardiovascular risk factors. *J Infect Public Health*. 2010 Dec;3(4):159-65. Epub 2010 Nov 9. PubMed PMID:21126720.

61. Killingley B, Greatorex J, Cauchemez S, Enstone JE, Curran M, Read RC, Lim WS, Hayward A, Nicholson KG, **Nguyen-Van-Tam JS**. Virus shedding and environmental deposition of novel A (H1N1) pandemic influenza virus: interim findings. *Health Technol Assess*. 2010 Oct;14(46):237-354. PubMed PMID: 20923613.
62. McLean E, Pebody RG, Campbell C, Chamberland M, Hawkins C, **Nguyen-Van-Tam JS**, Oliver I, Smith GE, Ihekweazu C, Bracebridge S, Maguire H, Harris R, Kafatos G, White PJ, Wynne-Evans E, Green J, Myers R, Underwood A, Dallman T, Wreghitt T, Zambon M, Ellis J, Phin N, Smyth B, McMenamin J, Watson JM. Pandemic (H1N1) 2009 influenza in the UK: clinical and epidemiological findings from the first few hundred (FF100) cases. *Epidemiol Infect*. 2010 Nov;138(11):1531-41. Epub 2010 Jul 1. PubMed PMID: 20594381.
63. Pebody RG, Harris R, Kafatos G, Chamberland M, Campbell C, **Nguyen-Van-Tam JS**, McLean E, Andrews N, White PJ, Wynne-Evans E, Green J, Ellis J, Wreghitt T, Bracebridge S, Ihekweazu C, Oliver I, Smith G, Hawkins C, Salmon R, Smyth B, McMenamin J, Zambon M, Phin N, Watson JM. Use of antiviral drugs to reduce household transmission of pandemic (H1N1) 2009, United Kingdom. *Emerg Infect Dis*. 2011 Jun;17(6):990-9. PubMed PMID: 21749759.
64. Brett SJ, Myles P, Lim WS, Enstone JE, Bannister B, Semple MG, Read RC, Taylor BL, McMenamin J, Nicholson KG, **Nguyen-Van-Tam JS**, Openshaw PJ; Influenza Clinical Information Network (FLU-CIN). Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. *PLoS ONE*. 2011 Apr 25;6(4):e18120. PubMed PMID: 21541017; PubMed Central PMCID: PMC3081811.
65. Troko J, Myles P, Gibson J, Hashim A, Enstone J, Kingdon S, Packham C, Amin S, Hayward A, **Nguyen Van-Tam J**. Is public transport a risk factor for acute respiratory infection? *BMC Infect Dis*. 2011 Jan 14;11:16. PubMed PMID: 21235795; PubMed Central PMCID: PMC3030548.
66. Nicoll A, Brown C, Karcher F, Penttinen P, Hegermann-Lindenchrone M, Villanueva S, Ciotti M, Jean-Gilles L, Rehmet S, **Nguyen-Van-Tam JS**. Developing pandemic preparedness in Europe in the 21st century: experience, evolution and next steps. *Bull World Health Organ*. 2012 Apr 1;90(4):311-7. PubMed PMID: 22511829; PubMed Central PMCID: PMC3324872.
67. Myles PR, **Nguyen-Van-Tam JS**, Lim WS, Nicholson KG, Brett SJ, Enstone JE, McMenamin J, Openshaw PJ, Read RC, Taylor BL, Bannister B, Semple MG. Comparison of CATs, CURB-65 and PMEWS as triage tools in pandemic influenza admissions to UK hospitals: case control analysis using retrospective data. *PLoS ONE*. 2012;7(4):e34428. Epub 2012 Apr 3. PubMed PMID: 22509303; PubMed Central PMCID: PMC3317953.
68. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB; GenISIS Investigators; MOSAIC Investigators (listed as **Nguyen-Van-Tam JS**), Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. IFITM3 restricts the morbidity and mortality associated with influenza. *Nature*. 2012 Mar 5;484(7395):519-23. doi: 10.1038/nature10921. PubMed PMID: 22446628.
69. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Bannister B, Nicholson KG, **Nguyen-Van-Tam JS**; on behalf of the Influenza Clinical Information Network (FLU-CIN). Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. *Thorax*. 2012 Mar 14. PubMed PMID: 22407890.

70. Bolotin S, Pebody R, White PJ, McMenamin J, Perera L, **Nguyen-Van-Tam JS**, Barlow T, Watson JM; UK Severe Influenza Surveillance System (USISS) Steering Group. A new sentinel surveillance system for severe influenza in England shows a shift in age distribution of hospitalised cases in the post-pandemic period. **PLoS ONE**. 2012;7(1):e30279. Epub 2012 Jan 23. PubMed PMID: 22291929; PubMed Central PMCID: PMC3264602.
71. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzdana A, Agboado G, Orton E, Bechard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figuereroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Penalver J, **Nguyen-Van-Tam JS**. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis from a public health policy perspective. **PLoS ONE**. 2011;6(12):e29249. Epub 2011 Dec 22. Review. PubMed PMID: 2216224; PubMed Central PMCID: PMC3245259.
72. Greatorex JS, Digard P, Curran MD, Moynihan R, Wensley H, Wreghitt T, Varsani H, Garcia F, Enstone J, **Nguyen-Van-Tam JS**. Survival of influenza A(H1N1) on materials found in households: implications for infection control. **PLoS ONE**. 2011;6(11):e27932. Epub 2011 Nov 22. PubMed PMID: 22132172; PubMed Central PMCID: PMC3222642.
73. Killingley B, Enstone JE, Greatorex J, Gilbert AS, Lambkin-Williams R, Cauchemez S, Katz JM, Booy R, Hayward A, Oxford J, Bridges CB, Ferguson NM, **Nguyen Van-Tam JS**. Use of a human influenza challenge model to assess person-to-person transmission: proof-of-concept study. **J Infect Dis**. 2012 Jan 1;205(1):35-43. Epub 2011 Nov 30. PubMed PMID: 22131338.
74. Hashim A, Jean-Gilles L, Hegermann-Lindencrone M, Shaw I, Brown C, **Nguyen-Van-Tam JS**. Did pandemic preparedness aid the response to pandemic (H1N1) 2009? A qualitative analysis in seven countries within the WHO European Region. **J Infect Public Health**. 2012 Aug;5(4):286-96. doi: 10.1016/j.jiph.2012.04.001. Epub 2012 May 22. PubMed PMID: 23021651.
75. Beck CR, McKenzie BC, Hashim AB, Harris RC; University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, **Nguyen-Van-Tam JS**. Influenza Vaccination for Immunocompromised Patients: Systematic Review and Meta-analysis by Etiology. **J Infect Dis**. 2012 Oct;206(8):1250-9. Epub 2012 Aug 16. PubMed PMID: 22904335.
76. Myles P, **Nguyen-Van-Tam JS**, Semple MG, Brett SJ, Bannister B, Read RC, Taylor BL, McMenamin J, Enstone JE, Nicholson KG, Openshaw P, Lim WS, Flu-Cin IC. Differences between asthmatics and non-asthmatics hospitalised with influenza A infection. **Eur Respir J**. 2012 Aug 16. PubMed PMID: 22903963.
77. Dolan GP, Myles PR, Brett SJ, Enstone JE, Read RC, Openshaw PJ, Semple MG, Lim WS, Taylor BL, McMenamin J, Nicholson KG, Bannister B, **Nguyen-Van-Tam JS**; Influenza Clinical Information Network (FLU-CIN). The comparative clinical course of pregnant and non-pregnant women hospitalised with influenza A(H1N1)pdm09 infection. **PLoS ONE**. 2012;7(8):e41638. Epub 2012 Aug 3. PubMed PMID: 22870239; PubMed Central PMCID: PMC3411676.

78. Dolan GP, Harris RC, Clarkson M, Sokal R, Morgan G, Mukaigawara M, Horiuchi H, Hale R, Stormont L, Bechard-Evans L, Chao YS, Eremin S, Martins S, Tam JS, Penalver J, Zanuzadana A, **Nguyen-Van-Tam JS**. Vaccination of health care workers to protect patients at increased risk for acute respiratory disease. *Emerg Infect Dis*. 2012 Aug;18(8):1225-34. doi: 10.3201/eid1808.111355. PubMed PMID: 22840895; PubMed Central PMCID: PMC3414018.
79. Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Armstrong C, Bannister B, Nicholson KG, **Nguyen-Van-Tam JS**; Influenza Clinical Information Network (FLU-CIN). Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. *Thorax*. 2012 Aug;67(8):709-17. Epub 2012 Mar 10. PubMed PMID: 22407890; PubMed Central PMCID: PMC3402749.
80. Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, **Nguyen-Van-Tam JS**. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. *J Infect Dis*. 2013 Feb 15;207(4):553-63. doi: 10.1093/infdis/jis726. Epub 2012 Nov 29. Review. PubMed PMID: 23204175; PubMed Central PMCID: PMC3549600.
81. Whitley RJ, Boucher CA, Lina B, **Nguyen-Van-Tam JS**, Osterhaus A, Schutten M, Monto AS. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). *Clin Infect Dis*. 2013 May;56(9):1197-205. doi: 10.1093/cid/cis1220. Epub 2013 Jan 10. PubMed PMID: 23307766.
82. Puleston R, Bugg G, Hoschler K, Konje J, Thornton J, Stephenson I, Myles P, Enstone J, Augustine G, Davis Y, Zambon M, Nicholson K, **Nguyen-Van-Tam J**. Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine. *PLoS ONE*. 2013;8(1):e47448. doi: 10.1371/journal.pone.0047448. Epub 2013 Jan 23. PubMed PMID: 23372640; PubMed Central PMCID: PMC3553100.
83. Thompson KA, Pappachan JV, Bennett AM, Mittal H, Macken S, Dove BK, **Nguyen-Van-Tam JS**, Copley VR, O'Brien S, Hoffman P, Parks S, Bentley A, Isalska B, Thomson G; EASE Study Consortium. Influenza aerosols in UK hospitals during the H1N1 (2009) pandemic--the risk of aerosol generation during medical procedures. *PLoS ONE*. 2013;8(2):e56278. doi: 10.1371/journal.pone.0056278. Epub 2013 Feb 13. PubMed PMID: 23418548; PubMed Central PMCID: PMC3571988.
84. Health Protection Agency (HPA) UK Novel Coronavirus Investigation team. Evidence of person-to-person transmission within a family cluster of novel coronavirus infections, United Kingdom, February 2013. *Euro Surveill*. 2013 Mar 14;18(11):20427. PubMed PMID: 23517868.
85. Beck CR, McKenzie BC, Hashim AB, Harris RC, Zanuzadana A, Agboado G, Orton E, Bechard-Evans L, Morgan G, Stevenson C, Weston R, Mukaigawara M, Enstone J, Augustine G, Butt M, Kim S, Puleston R, Dabke G, Howard R, O'Boyle J, O'Brien M, Ahyow L, Denness H, Farmer S, Figuereroa J, Fisher P, Greaves F, Haroon M, Haroon S, Hird C, Isba R, Ishola DA, Kerac M, Parish V, Roberts J, Rosser J, Theaker S, Wallace D, Wigglesworth N, Lingard L, Vinogradova Y, Horiuchi H, Penalver J, **Nguyen-Van-Tam JS**. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis. *Influenza Other Respir Viruses*. 2013 Sep;7 Suppl 2:72-5. doi: 10.1111/irv.12084. PubMed PMID: 24034488.

86. Semple MG, Myles PR, Nicholson KG, Lim WS, Read RC, Taylor BL, Brett SJ, Openshaw PJ, Enstone JE, McMenamin J, Bannister B, **Nguyen-Van-Tam JS**. An Evaluation of Community Assessment Tools (CATs) in Predicting Use of Clinical Interventions and Severe Outcomes during the A(H1N1)pdm09 Pandemic. **PLoS ONE**. 2013 Sep 19;8(9):e75384. doi: 10.1371/journal.pone.0075384. PubMed PMID: 24069409; PubMed Central PMCID: PMC3777884.
87. Beyer WE, McElhaney J, Smith DJ, Monto AS, **Nguyen-Van-Tam JS**, Osterhaus AD. Cochrane re-arranged: Support for policies to vaccinate elderly people against influenza. **Vaccine**. 2013 Oct 3. doi:pii: S0264-410X(13)01339-X.10.1016/j.vaccine.2013.09.063. PubMed PMID: 24095882.
88. Puleston RL, Mallaghan CM, Modha DE, Hunter PR, **Nguyen-Van-Tam JS**, Regan CM, Nichols GL, Chalmers RM. The first recorded outbreak of cryptosporidiosis due to *Cryptosporidium cuniculus* (formerly rabbit genotype), following a water quality incident. **J Water Health**. 2014 Mar;12(1):41-50. doi: 10.2166/wh.2013.097. PubMed PMID: 24642431.
89. Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, Ferguson N, Goonetilleke N, Harvey G, Kovar J, Lim MS, McMichael A, Millett ER, **Nguyen-Van-Tam JS**, Nazareth I, Pebody R, Tabassum F, Watson JM, Wurie FB, Johnson AM, Zambon M; on behalf of the Flu Watch Group. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. **Lancet Respir Med**. 2014 Mar 17. pii: S2213-2600(14)70034-7. doi: 10.1016/S2213-2600(14)70034-7. [Epub ahead of print] PubMed PMID: 24717637.
90. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Al Khuwaitir TS, Al Mamun A, Anovadiya AP, Azziz-Baumgartner E, Báez C, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarría M, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoger PH, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Knight M, Kudo K, Kuznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Mayo-Montero E, McGeer A, Memish Z, Metan G, Mickiene A, Mikić D, Mohn KG, Moradi A, Nymadawa P, Oliva ME, Ozkan M, Parekh D, Paul M, Polack FP, Rath BA, Rodríguez AH, Sarrouf EB, Seale AC, Sertogullarindan B, Siqueira MM, Skreät-Magierło J, Stephan F, Talarek E, Tang JW, To KK, Torres A, Törün SH, Tran D, Uyeki TM, Van Zwol A, Vaudry W, Vidmar T, Yokota RT, Zarogoulidis P; PRIDE Consortium Investigators, **Nguyen-Van-Tam JS**. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. **Lancet Respir Med**. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19. Review. PubMed PMID: 24815805.
92. Nyland GA, McKenzie BC, Myles PR, Semple MG, Lim WS, Openshaw PJ, Read RC, Taylor BL, Brett SJ, McMenamin J, Enstone JE, Bannister B, Nicholson KG, **Nguyen-Van-Tam JS**. Effect of ethnicity on care pathway and outcomes in patients hospitalized with influenza A(H1N1)pdm09 in the UK. **Epidemiol Infect**. 2015 Apr;143(6):1129-38. doi: 10.1017/S0950268814001873. Epub 2014 Aug 1. PubMed PMID: 25084481.
93. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, **Nguyen-Van-Tam JS**, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. **J Infect Dis**. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16. PMID: 25030060.

94. Barasheed O, Rashid H, Heron L, Ridda I, Haworth E, **Nguyen-Van-Tam J**, Dwyer DE, Booy R; Hajj Research Team.  
Influenza vaccination among Australian Hajj pilgrims: uptake, attitudes, and barriers.  
*J Travel Med.* 2014 Nov-Dec;21(6):384-90. doi: 10.1111/jtm.12146. Epub 2014 Aug 21. PubMed PMID: 25145836.
95. Elderfield RA, Watson SJ, Godlee A, Adamson WE, Thompson CI, Dunning J, Fernandez-Alonso M, Blumenkrantz D, Hussell T; MOSAIC Investigators (**Nguyen-Van-Tam JS**), Zambon M, Openshaw P, Kellam P, Barclay WS.  
Accumulation of human-adapting mutations during circulation of A(H1N1)pdm09 influenza virus in humans in the United Kingdom.  
*J Virol.* 2014 Nov;88(22):13269-83. doi: 10.1128/JVI.01636-14. Epub 2014 Sep 10. PubMed PMID: 25210166; PubMed Central PMCID: PMC4249111.
96. Rodrigo C, Leonardi-Bee J, **Nguyen-Van-Tam JS**, Lim WS. Effect of Corticosteroid Therapy on Influenza-Related Mortality: A Systematic Review and Meta-analysis.  
*J Infect Dis.* 2014 Nov 18. pii: jiu645. [Epub ahead of print] PubMed PMID: 25406333.
97. Okoli GN, Otete HE, Beck CR, **Nguyen-Van-Tam JS**. Use of neuraminidase inhibitors for rapid containment of influenza: a systematic review and meta-analysis of individual and household transmission studies.  
*PLoS One.* 2014 Dec 9;9(12):e113633. doi: 10.1371/journal.pone.0113633. eCollection 2014. PubMed PMID: 25490762; PubMed Central PMCID: PMC4260958.
98. Mateus AL, Otete HE, Beck CR, Dolan GP, **Nguyen-Van-Tam JS**. Effectiveness of travel restrictions in the rapid containment of human influenza: a systematic review.  
*Bull World Health Organ.* 2014 Dec 1;92(12):868-880D. doi: 10.2471/BLT.14.135590. Epub 2014 Sep 29. Review. PubMed PMID: 25552771; PubMed Central PMCID: PMC4264390.
99. Newitt S, Myles PR, Birkin JA, Maskell V, Slack RC, **Nguyen-Van-Tam JS**, Szatkowski L. Impact of infection control interventions on rates of Staphylococcus aureus bacteraemia in National Health Service acute hospitals, East Midlands, UK, using interrupted time-series analysis.  
*J Hosp Infect.* 2015 Jan 15. pii: S0195-6701(15)00034-1. doi: 10.1016/j.jhin.2014.12.016. PubMed PMID: 25659447.
100. Lim WS, Brittain C, Duley L, Edwards S, Gordon S, Montgomery A, **Nguyen-Van-Tam J**, Read R, Whitham D, Whynes D, Woodhead M, Wootton D.  
Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial 'in hibernation', ready for rapid activation.  
*Health Technol Assess.* 2015 Feb;19(16):1-78. doi: 10.3310/hta19160. PubMed PMID: 25716702.
101. Aoyagi Y, Beck CR, Dingwall R, **Nguyen-Van-Tam JS**.  
Healthcare workers' willingness to work during an influenza pandemic: a systematic review and meta-analysis.  
*Influenza Other Respir Viruses.* 2015 Mar 24. doi:10.1111/irv.12310. [Epub ahead of print] PubMed PMID: 25807865.
102. Hayward AC, Wang L, Goonetilleke N, Fragaszy EB, Bermingham A, Copas A, Dukes O, Millett ER, Nazareth I, **Nguyen-Van-Tam JS**, Watson JM, Zambon M, Johnson AM, McMichael AJ; Flu Watch Group.  
Natural T Cell Mediated Protection Against Seasonal and Pandemic Influenza: Results of the Flu Watch Cohort Study.  
*Am J Respir Crit Care Med.* 2015 Apr 6. [Epub ahead of print] PubMed PMID: 25844934.

103. Wang M, Barasheed O, Rashid H, Booy R, El Bashir H, Haworth E, Ridda I, Holmes EC, Dwyer DE, **Nguyen-Van-Tam J**, Memish ZA, Heron L.  
A cluster-randomised controlled trial to test the efficacy of facemasks in preventing respiratory viral infection among Hajj pilgrims.  
*J Epidemiol Glob Health*. 2015 Jun;5(2):181-9. doi: 10.1016/j.jegh.2014.08.002. Epub 2014 Oct 2. PubMed PMID: 25922328.
104. Wallace D, Myles P, Holt R, **Nguyen-Van-Tam J**.  
Evaluation of the 'Live Life Better' Service: a community-based weight management service for morbidly obese patients.  
*J Publ Health (Oxf)*. 2016 Jun; 38(2);e138-49. doi:10.1093/pubmed/fdv103. PMID: 26311828
105. Nakafero G, Sanders RD, **Nguyen-Van-Tam JS**, Myles PR.  
Association between benzodiazepine use and exacerbations and mortality in patients with asthma: a matched case-control and survival analysis using the United Kingdom Clinical Practice Research Datalink.  
*Pharmacoepidemiol Drug Saf*. 2015 Aug;24(8):793-802. doi: 10.1002/pds.3799. Epub 2015 May 27. PubMed PMID: 26013409.
106. Venkatesan S, Myles PR, McCann G, Kousoulis AA, Hashmi M, Belatri R, Boyle E, Barcroft A, van Staa TP, Kirkham JJ, **Nguyen Van Tam JS**, Williams TJ, Semple MG.  
Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study.  
*Health Technol Assess*. 2015 Oct;19(89):1-132. doi: 10.3310/hta19890. PubMed PMID: 26514069.
107. Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Mamun AA, Anovadiya AP, Araújo WN, Azziz-Baumgartner E, Báez C, Bantar C, Barhoush MM, Bassetti M, Beovic B, Bingisser R, Bonmarin I, Borja-Aburto VH, Cao B, Carratala J, Cuezco MR, Denholm JT, Dominguez SR, Duarte PA, Dubnov-Raz G, Echavarria M, Fanella S, Fraser J, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Iglesias AL, Hoeger PH, Hoffmann M, Hu X, Islam QT, Jiménez MF, Kandeel A, Keijzers G, Khalili H, Khandaker G, Knight M, Kuznierz G, Kuzman I, Kwan AM, Amine IL, Langenegger E, Lankarani KB, Leo YS, Linko R, Liu P, Madanat F, Manabe T, Mayo-Montero E, McGeer A, Memish ZA, Metan G, Mikić D, Mohn KG, Moradi A, Nymadawa P, Ozbay B, Ozkan M, Parekh D, Paul M, Poepl W, Polack FP, Rath BA, Rodríguez AH, Siqueira MM, Skrzęć-Magierło J, Talarek E, Tang JW, Torres A, Törün SH, Tran D, Uyeki TM, van Zwol A, Vaudry W, Velyvyte D, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators, **Nguyen-Van-Tam JS**.  
Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an IPD meta-analysis.  
*Influenza Other Respir Viruses*. 2015 Nov 25. doi: 10.1111/irv.12363. PubMed PMID: 26602067.
108. Fragaszy E, Ishola DA, Brown IH, Enstone J, **Nguyen-Van-Tam JS**, Simons R, Tucker AW, Wieland B, Williamson SM, Hayward AC; Flu Watch Group, Wood JL; Combating Swine Influenza (COSI) Consortium.  
Increased risk of A(H1N1)pdm09 influenza infection in UK pig industry workers compared to a general population cohort.  
*Influenza Other Respir Viruses*. 2015 Nov 27. doi: 10.1111/irv.12364. PubMed PMID: 26611769.
109. Killingley B, Greatorex J, Digard P, Wise H, Garcia F, Varsani H, Cauchemez S, Enstone JE, Hayward A, Curran MD, Read RC, Lim WS, Nicholson KG, **Nguyen-Van-Tam JS**.  
The environmental deposition of influenza virus from patients infected with influenza (H1N1)pdm09: Implications for infection prevention and control.  
*J Infect Public Health*. 2015 Dec 1. pii: S1876-0341(15)00192-6. doi:10.1016/j.jiph.2015.10.009. PubMed PMID: 26653976.
110. Browne A, St-Onge Ahmad S, Beck CR, **Nguyen-Van-Tam JS**.  
The roles of transportation and transportation hubs in the propagation of influenza and coronaviruses: a systematic review.  
*J Travel Med*. 2016 Jan 18;23(1). pii: tav002. doi: 10.1093/jtm/tav002. Review. PubMed PMID: 26782122.

111. French CE, McKenzie BC, Coope C, Rajanaidu S, Paranthaman K, Pebody R, **Nguyen-Van-Tam JS**; Noso-RSV Study Group, Higgins JP, Beck CR. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. *Influenza Other Respir Viruses*. 2016 Feb 22. doi: 10.1111/irv.12379. Review. PubMed PMID: 26901358.
112. Fragaszy EB, Warren-Gash C, Wang L, Copas A, Dukes O, Edmunds WJ, Goonetilleke N, Harvey G, Johnson AM, Kovar J, Lim MS, McMichael A, Millett ER, Nazareth I, **Nguyen-Van-Tam JS**, Tabassum F, Watson JM, Wurie F, Zambon M, Hayward AC; Flu Watch Group. Cohort Profile: The Flu Watch Study. *Int J Epidemiol*. 2016. PMID: 26940466.
113. Rodrigo C, Leonardi-Bee J, **Nguyen-Van-Tam J**, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. *Cochrane Database Syst Rev*. 2016 Mar 7;3:CD010406. doi: 10.1002/14651858.CD010406.pub2. PubMed PMID: 26950335.
114. Nakafero G, Sanders RD, **Nguyen-Van-Tam JS**, Myles PR. The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK Primary Care data. *Pharmacoepidemiol Drug Saf*. 2016. doi: 10.1002/pds.4028. PubMed PMID: 27215827.
115. Venkatesan S, Myles PR, Leonardi-Bee J, Muthuri SG, Al Masri M, Andrews N, Bantar C, Dubnov-Raz G, Gérardin P, Koay ES, Loh TP, Memish Z, Miller E, Oliva ME, Rath BA, Schweiger B, Tang JW, Tran D, Vidmar T, Waight PA, **Nguyen-Van-Tam JS**. Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an Individual Participant Data (IPD) meta-analysis. *Clin Infect Dis*. 2017 Feb 12. doi: 10.1093/cid/cix127. PubMed PMID: 28199524.
116. Lansbury LE, Smith S, Beyer W, Karamelic E, Pasic-Juhas E, Sikira H, Mateus A, Oshitani H, Zhao H, Beck CR, **Nguyen-Van-Tam JS**. Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis. *Vaccine*. 2017 Apr 11;35(16):1996-2006. doi: 10.1016/j.vaccine.2017.02.059. Epub 2017 Mar 14. Review. PubMed PMID: 28302409.
117. Watson SI, Chen YF, **Nguyen-Van-Tam JS**, Myles PR, Venkatesan S, Zambon M, Uthman O, Chilton PJ, Lilford RJ. Evidence synthesis and decision modelling to support complex decisions: stockpiling neuraminidase inhibitors for pandemic influenza usage. Version 2. *FI000Res*. 2016 Sep 12 [revised 2017 Jan 1];5:2293. doi: 10.12688/fi000research.9414.2. eCollection 2016. PubMed PMID: 28413608;
118. Lansbury LE, Brown CS, **Nguyen-Van-Tam JS**. Influenza in long-term care facilities. *Influenza Other Respir Viruses*. 2017 ep;11(5):356-366. doi: 10.1111/irv.12464. Epub 2017 Jul 26. Review. PubMed PMID: 28691237.
119. Alimi Y, Lim WS, Lansbury L, Leonardi-Bee J, **Nguyen-Van-Tam JS**. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. *J Clin Virol*. 2017 Oct;95:26-35. doi: 10.1016/j.jcv.2017.07.019. Epub 2017 Aug 5. Review. PubMed PMID: 28837859.

120. Fragaszy EB, Warren-Gash C, White PJ, Zambon M, Edmunds WJ, **Nguyen-Van-Tam JS**, Hayward AC; Flu Watch Group.  
Effects of seasonal and pandemic influenza on health-related quality of life, work and school absence in England: Results from the Flu Watch cohort study.  
**Influenza Other Respir Viruses**. 2018 Jan;12(1):171-182. doi: 10.1111/irv.12506. PubMed PMID: 28991409.
121. Lina B, Boucher C, Osterhaus A, Monto AS, Schutten M, Whitley RJ, **Nguyen-Van-Tam JS**.  
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study.  
**Influenza Other Respir Viruses**. 2018 Mar;12(2):267-278. doi: 10.1111/irv.12534. Epub 2018 Jan 15. PubMed PMID: 29265727.
122. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, Ehrman S, Milton DK; **EMIT Consortium**.  
Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community.  
**Proc Natl Acad Sci USA**. 2018 Jan 30;115(5):1081-1086. doi: 10.1073/pnas.1716561115. Epub 2018 Jan 18. PubMed PMID: 29348203.
123. Bradbury N, **Nguyen-Van-Tam J**, Lim WS.  
Clinicians' attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza.  
**BMC Health Serv Res**. 2018 May 2;18(1):311. doi: 10.1186/s12913-018-3122-x. PubMed PMID: 29716584.
124. Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, Bloom CI, Chaussabel D, Banchereau J, Brett SJ; **MOSAIC Investigators**, Moffatt MF, O'Garra A, Openshaw PJM.  
Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. **Nat Immunol**. 2018 Jun;19(6):625-635. doi: 10.1038/s41590-018-0111-5. Epub 2018 May 18. PubMed PMID: 29777224.
125. Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, **Nguyen-Van-Tam JS**, Abhishek A.  
Predictors and temporal trend of flu vaccination in auto-immune rheumatic diseases in the UK: a nationwide prospective cohort study.  
**Rheumatology (Oxford)**. 2018 Oct 1;57(10):1726-1734. doi: 10.1093/rheumatology/key156. PubMed PMID: 9901743.
126. Venkatesan S, Carias C, Biggerstaff M, Campbell AP, **Nguyen-Van-Tam JS**, Kahn E, Myles PR, Meltzer MI.  
Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.  
**J Public Health (Oxf)**. 2018 Jun 28. doi: 10.1093/pubmed/fdy108. PubMed PMID: 29955851.
127. Ikonen N, Savolainen-Kopra C, Enstone JE, Kulmala I, Pasanen P, Salmela A, Salo S, **Nguyen-Van-Tam JS**, Ruutu P; PANDHUB consortium.  
Deposition of respiratory virus pathogens on frequently touched surfaces at airports.  
**BMC Infect Dis**. 2018 Aug 29;18(1):437. doi: 10.1186/s12879-018-3150-5. PubMed PMID: 30157776.
128. Ramos-Sevillano E, Wade WG, Mann A, Gilbert A, Lambkin-Williams R, Killingley B, **Nguyen-Van-Tam JS**, Tang CM.  
The Effect of Influenza Virus on the Human Oropharyngeal Microbiome.  
**Clin Infect Dis**. 2019 May 30;68(12):1993-2002. doi: 10.1093/cid/ciy821. PMID: 30445563; PMCID: PMC6541733.

129. Lansbury L, Rodrigo C, Leonardi-Bee J, **Nguyen-Van-Tam J**, Lim WS.  
Corticosteroids as adjunctive therapy in the treatment of influenza.  
**Cochrane Database Syst Rev.** 2019 Feb 24;2(2):CD010406. doi: 10.1002/14651858.CD010406.pub3.  
PMID: 30798570; PMCID: PMC6387789.
130. Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, **Nguyen-Van-Tam JS**, Abhishek A.  
Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink.  
**Ann Rheum Dis.** 2019 Aug;78(8):1122-1126. doi: 10.1136/annrheumdis-2019-215086. Epub 2019 Apr 29.  
PMID: 31036623; PMCID: PMC6691866.
131. Venkatesan S, Myles PR, Bolton KJ, Muthuri SG, Al Khuwaitir T, Anovadiya AP, Azziz-Baumgartner E, Bajjou T, Bassetti M, Beovic B, Bertisch B, Bonmarin I, Booy R, Borja-Aburto VH, Burgmann H, Cao B, Carratala J, Chinbayar T, Cilloniz C, Denholm JT, Dominguez SR, Duarte PAD, Dubnov-Raz G, Fanella S, Gao Z, Gérardin P, Giannella M, Gubbels S, Herberg J, Higuera Iglesias AL, Hoeger PH, Hu XY, Islam QT, Jiménez MF, Keijzers G, Khalili H, Kuszniierz G, Kuzman I, Langenegger E, Lankarani KB, Leo YS, Libster RP, Linko R, Madanat F, Maltezos E, Mamun A, Manabe T, Metan G, Mickiene A, Mikić D, Mohn KGI, Oliva ME, Ozkan M, Parekh D, Paul M, Rath BA, Refaey S, Rodríguez AH, Sertogullarindan B, Skreč-Magierło J, Somer A, Talarek E, Tang JW, To K, Tran D, Uyeki TM, Vaudry W, Vidmar T, Zarogoulidis P; PRIDE Consortium Investigators. **Nguyen-Van-Tam JS**.  
Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.  
**J Infect Dis.** 2020 Jan 14;221(3):356-366. doi: 10.1093/infdis/jiz152. PMID: 31314899; PMCID: PMC7313925.
132. Jenkin DC, Mahgoub H, Morales KF, Lambach P, **Nguyen-Van-Tam JS**.  
A rapid evidence appraisal of influenza vaccination in health workers: An important policy in an area of imperfect evidence.  
**Vaccine X.** 2019 Jul 11;2:100036. doi: 10.1016/j.jvacx.2019.100036. PMID: 31384750; PMCID: PMC6668237.
133. Cherian T, Morales KF, Mantel C, Lambach P; Independent Expert Advisory Group (IEAG) for Health Worker Influenza Vaccination.  
Factors and considerations for establishing and improving seasonal influenza vaccination of health workers: Report from a WHO meeting, January 16-17, Berlin, Germany.  
**Vaccine.** 2019 Oct 8;37(43):6255-6261. doi: 10.1016/j.vaccine.2019.07.079. Epub 2019 Sep 6. PMID: 31500965; PMCID: PMC6868506.
134. Roosenhoff R, Reed V, Kenwright A, Schutten M, Boucher CA, Monto A, Clinch B, Kumar D, Whitley R, **Nguyen-Van-Tam JS**, Osterhaus ADME, Fouchier RAM, Fraaij PLA.  
Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS).  
**Clin Infect Dis.** 2019 Sep 27:ciz939. doi: 10.1093/cid/ciz939. PMID: 31560055.
135. Venkatesan S, **Nguyen-Van-Tam JS**, Siebers PO.  
A novel framework for evaluating the impact of individual decision-making on public health outcomes and its potential application to study antiviral treatment collection during an influenza pandemic.  
**PLoS One.** 2019 Oct 17;14(10):e0223946. doi: 10.1371/journal.pone.0223946. PMID: 31622404; PMCID: PMC6797120.
136. Lansbury LE, Rodrigo C, Leonardi-Bee J, **Nguyen-Van-Tam J**, Shen Lim W.  
Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis.  
**Crit Care Med.** 2020 Feb;48(2):e98-e106. doi: 10.1097/CCM.0000000000004093. PMID: 31939808.

137. Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, **Nguyen-Van-Tam JS**, Abhishek A.  
Effectiveness of inactivated influenza vaccine in autoimmunehrheumatic diseases treated with disease-modifying anti-rheumatic drugs.  
**Rheumatology (Oxford)**. 2020 Dec 1;59(12):3666-3675. doi: 10.1093/rheumatology/keaa078. PMID: 32160295; PMCID: PMC7733714.
138. Mehta NS, Mytton OT, Mullins EWS, Fowler TA, Falconer CL, Murphy OB, Langenberg C, Jayatunga WJP, Eddy DH, **Nguyen-Van-Tam JS**. SARS-CoV-2 (COVID-19):  
What Do We Know About Children? A Systematic Review.  
**Clin Infect Dis**. 2020 Dec 3;71(9):2469-2479. doi: 10.1093/cid/ciaa556. PMID: 32392337; PMCID: PMC7239259.
139. Swann OV, Holden KA, Turtle L, Pollock L, Fairfield CJ, Drake TM, Seth S, Egan C, Hardwick HE, Halpin S, Girvan M, Donohue C, Pritchard M, Patel LB, Ladhani S, Sigfrid L, Sinha IP, Olliaro PL, **Nguyen-Van-Tam JS**, Horby PW, Merson L, Carson G, Dunning J, Openshaw PJM, Baillie JK, Harrison EM, Docherty AB, Semple MG; ISARIC4C Investigators.  
Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study.  
**BMJ**. 2020 Aug 27;370:m3249. doi: 10.1136/bmj.m3249. PMID: 32960186; PMCID: PMC7488201.
140. Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Gupta R, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, **Nguyen-Van-Tam JS**, Norman L, Noursadeghi M, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LC, Openshaw PJ, Baillie JK, Semple MG, Docherty AB, Harrison EM; ISARIC4C investigators.  
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score.  
**BMJ**. 2020 Sep 9;370:m3339. doi: 10.1136/bmj.m3339. Erratum in: **BMJ**. 2020 Nov 13;371:m4334. PMID: 32907855; PMCID: PMC7116472.
141. Bueno de Mesquita PJ, **Nguyen-Van-Tam J**, Killingley B, Enstone J, Lambkin-Williams R, Gilbert AS, Mann A, Forni J, Yan J, Pantelic J, Grantham ML, Milton DK.  
Influenza A (H3) illness and viral aerosol shedding from symptomatic naturally infected and experimentally infected cases.  
**Influenza Other Respir Viruses**. 2021 Jan;15(1):154-163. doi: 10.1111/irv.12790. Epub 2020 Jul 23. PMID: 32705798; PMCID: PMC7767952.
142. **Nguyen-Van-Tam JS**, Killingley B, Enstone J, Hewitt M, Pantelic J, Grantham ML, Bueno de Mesquita PJ, Lambkin-Williams R, Gilbert A, Mann A, Forni J, Noakes CJ, Levine MZ, Berman L, Lindstrom S, Cauchemez S, Bischoff W, Tellier R, Milton DK; EMIT Consortium.  
Minimal transmission in an influenza A (H3N2) human challenge-transmission model within a controlled exposure environment.  
**PLoS Pathog**. 2020 Jul 13;16(7):e1008704. doi: 10.1371/journal.ppat.1008704. PMID: 32658939; PMCID: PMC7390452.
143. **Nguyen-Van-Tam J**, Wyffels V, Smulders M, Mazumder D, Tyagi R, Gupta N, Gavart S, Fleischhackl R.  
Cumulative incidence of post-infection asthma or wheezing among young children clinically diagnosed with respiratory syncytial virus infection in the United States: A retrospective database analysis.  
**Influenza Other Respir Viruses**. 2020 Nov;14(6):730-738. doi: 10.1111/irv.12770. Epub 2020 Jun 12. PMID: 32533658; PMCID: PMC7578296.
144. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, **Nguyen-Van-Tam JS**, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators.  
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.  
**BMJ**. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985. PMID: 32444460; PMCID: PMC7243036.

145. Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, Abubakar I, Lipman M, Quartagno M, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, **Nguyen-Van-Tam JS**, Norman L, Olliaro PL, Pritchard MG, Russell CD, Scott-Brown J, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle L, Openshaw PJM, Baillie JK, Semple MG, Noursadeghi M; ISARIC4C Investigators.  
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study.  
*Lancet Respir Med*. 2021 Jan 11:S2213-2600(20)30559-2. doi: 10.1016/S2213-2600(20)30559-2. Epub ahead of print. PMID: 33444539; PMCID: PMC7832571.
146. Al-Beltagi S, Preda CA, Goulding LV, James J, Pu J, Skinner P, Jiang Z, Wang BL, Yang J, Banyard AC, Mellits KH, Gershkovich P, Hayes CJ, **Nguyen-Van-Tam J**, Brown IH, Liu J, Chang KC.  
Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.  
*Viruses*. 2021 Feb 3;13(2):234. doi: 10.3390/v13020234. PMID: 33546185; PMCID: PMC7913267.
147. Bloom CI, Drake TM, Docherty AB, Lipworth BJ, Johnston SL, **Nguyen-Van-Tam JS**, Carson G, Dunning J, Harrison EM, Baillie JK, Semple MG, Cullinan P, Openshaw PJM; ISARIC investigators.  
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK.  
*Lancet Respir Med*. 2021 Jul;9(7):699-711. doi: 10.1016/S2213-2600(21)00013-8. Epub 2021 Mar 4. PMID: 33676593; PMCID: PMC8241313.
148. Moreno G, Rodríguez A, Sole-Violán J, Martín-Loeches I, Díaz E, Bodí M, Reyes LF, Gómez J, Guardiola J, Trefler S, Vidaur L, Papiol E, Socías L, García-Vidal C, Correig E, Marín-Corral J, Restrepo MI, **Nguyen-Van-Tam JS**, Torres A.  
Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia.  
*ERJ Open Res*. 2021 Mar 8;7(1):00888-2020. doi: 10.1183/23120541.00888-2020. PMID: 33718494; PMCID: PMC7938052.
149. Okoli GN, Racovitan F, Abdulwahid T, Hyder SK, Lansbury L, Righolt CH, Mahmud SM, **Nguyen-Van-Tam JS**.  
Decline in Seasonal Influenza Vaccine Effectiveness With Vaccination Program Maturation: A Systematic Review and Meta-analysis.  
*Open Forum Infect Dis*. 2021 Feb 5;8(3):ofab069. doi: 10.1093/ofid/ofab069. PMID: 33738320; PMCID: PMC7953658.
150. Docherty AB, Mulholland RH, Lone NI, Cheyne CP, De Angelis D, Diaz-Ordaz K, Donegan C, Drake TM, Dunning J, Funk S, García-Fiñana M, Girvan M, Hardwick HE, Harrison J, Ho A, Hughes DM, Keogh RH, Kirwan PD, Leeming G, **Nguyen Van-Tam JS**, Pius R, Russell CD, Spencer RG, Tom BD, Turtle L, Openshaw PJ, Baillie JK, Harrison EM, Semple MG; ISARIC4C Investigators.  
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK.  
*Lancet Respir Med*. 2021 Jul;9(7):773-785. doi: 10.1016/S2213-2600(21)00175-2. Epub 2021 May 14. PMID: 34000238; PMCID: PMC8121531.
151. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, Sigfrid L, Harrison EM, Docherty AB, de Silva TI, Egan C, Pius R, Hardwick HE, Merson L, Girvan M, Dunning J, **Nguyen-Van-Tam JS**, Openshaw PJM, Baillie JK, Semple MG, Ho A; ISARIC4C investigators.  
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.  
*Lancet Microbe*. 2021 Jun 2. doi: 10.1016/S2666-5247(21)00090-2. Epub ahead of print. PMID: 34100002; PMCID: PMC8172149.

152. Drake TM, Riad AM, Fairfield CJ, Egan C, Knight SR, Pius R, Hardwick HE, Norman L, Shaw CA, McLean KA, Thompson AAR, Ho A, Swann OV, Sullivan M, Soares F, Holden KA, Merson L, Plotkin D, Sigfrid L, de Silva TI, Girvan M, Jackson C, Russell CD, Dunning J, Solomon T, Carson G, Olliaro P, **Nguyen-Van-Tam JS**, Turtle L, Docherty AB, Openshaw PJ, Baillie JK, Harrison EM, Semple MG; ISARIC4C investigators.  
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study.  
*Lancet*. 2021 Jul 17;398(10296):223-237. doi: 10.1016/S0140-6736(21)00799-6. PMID: 34274064; PMCID: PMC8285118.
153. Liu X, Shaw RH, Stuart ASV, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Dinesh T, England A, Faust SN, Ferreira DM, Finn A, Green CA, Hallis B, Heath PT, Hill H, Lambe T, Lazarus R, Libri V, Long F, Mujadidi YF, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Singh N, Turner DPJ, Turner PJ, Walker LL, White R, **Nguyen-Van-Tam JS**, Snape MD; Com-COV Study Group.  
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.  
*Lancet*. 2021 Aug 6:S0140-6736(21)01694-9. doi: 10.1016/S0140-6736(21)01694-9. Epub ahead of print. PMID: 34370971; PMCID: PMC8346248.
154. Read JM, Green CA, Harrison EM, Docherty AB, Funk S, Harrison J, Girvan M, Hardwick HE, Turtle L, Dunning J, **Nguyen-Van-Tam JS**, Openshaw PJ, Baillie JK, Semple MG; ISARIC4C investigators.  
Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave.  
*Lancet*. 2021 Aug 12:S0140-6736(21)01786-4. doi: 10.1016/S0140-6736(21)01786-4. Epub ahead of print. PMID: 34391505; PMCID: PMC8360701.
155. Hippisley-Cox J, Coupland CA, Mehta N, Keogh RH, Diaz-Ordaz K, Khunti K, Lyons RA, Kee F, Sheikh A, Rahman S, Valabhji J, Harrison EM, Sellen P, Haq N, Semple MG, Johnson PWM, Hayward A, **Nguyen-Van-Tam JS**.  
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study.  
*BMJ*. 2021 Sep 17;374:n2244. doi: 10.1136/bmj.n2244. Erratum in: *BMJ*. 2021 Sep 20;374:n2300. PMID: 34535466; PMCID: PMC8446717.
156. Belazi S, Olsen SJ, Brown C, Green HK, Mook P, **Nguyen-Van-Tam J**, Penttinen P, Lansbury L.  
Spotlight influenza: Laboratory-confirmed seasonal influenza in people with acute respiratory illness: a literature review and meta-analysis, WHO European Region, 2004 to 2017.  
*Euro Surveill*. 2021 Sep;26(39):2000343. doi: 10.2807/1560-7917.ES.2021.26.39.2000343. PMID: 34596019; PMCID: PMC8485580.
157. Sullivan MK, Lees JS, Drake TM, Docherty AB, Oates G, Hardwick HE, Russell CD, Merson L, Dunning J, **Nguyen-Van-Tam JS**, Openshaw P, Harrison EM, Baillie JK; ISARIC4C Investigators.  
Acute kidney injury in patients hospitalised with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study.  
*Nephrol Dial Transplant*. 2021 Oct 18:gfab303. doi: 10.1093/ndt/gfab303. Epub ahead of print. PMID: 34661677.
158. Lazarus R, Baos S, Cappel-Porter H, Carson-Stevens A, Clout M, Culliford L, Emmett SR, Garstang J, Gbadamoshi L, Hallis B, Harris RA, Hutton D, Jacobsen N, Joyce K, Kaminski R, Libri V, Middleditch A, McCullagh L, Moran E, Phillipson A, Price E, Ryan J, Thirard R, Todd R, Snape MD, Tucker D, Williams RL, **Nguyen-Van-Tam JS**, Finn A, Rogers CA; ComfluCOV Trial Group.  
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.  
*Lancet*. 2021 Nov 11:S0140-6736(21)02329-1. doi: 10.1016/S0140-6736(21)02329-1. Epub ahead of print. PMID: 34774197; PMCID: PMC8585490.

159. Knight SR, Gupta RK, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA, Halpin S, Hardwick HE, Holden KA, Horby PW, Jackson C, Mclean KA, Merson L, **Nguyen-Van-Tam JS**, Norman L, Olliaro PL, Pritchard MG, Russell CD, Shaw CA, Sheikh A, Solomon T, Sudlow C, Swann OV, Turtle LCW, Openshaw PJM, Baillie JK, Docherty A, Semple MG, Noursadeghi M, Harrison EM; ISARIC Coronavirus Clinical Characterisation Consortium (ISARIC4C) Investigators; ISARIC4C investigators.  
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol.  
*Thorax*. 2021 Nov 22;thoraxjnl-2021-217629. doi: 10.1136/thoraxjnl-2021-217629. Epub ahead of print. PMID: 34810237; PMCID: PMC8610617.
160. Lansbury L, Rodrigo C, Leonardi-Bee J, **Nguyen-Van-Tam J**, Shen Lim W. Corticosteroids as adjunctive therapy in the treatment of influenza.  
*Emergencias*. 2021 Dec;33(6):466-467. Spanish, English. PMID: 34813195.
161. Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dodd K, Enever Y, Gokani K, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Murira J, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Salkeld J, Saralaya D, Sharma S, Sheridan R, Sturdy A, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, **Nguyen-Van-Tam JS**, Snape MD, Liu X, Faust SN; COV-BOOST study group.  
Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.  
*Lancet*. 2021 Dec 2:S0140-6736(21)02717-3. doi: 10.1016/S0140-6736(21)02717-3. Epub ahead of print. PMID: 34863358.
162. Stuart ASV, Shaw RH, Liu X, Greenland M, Aley PK, Andrews NJ, Cameron JC, Charlton S, Clutterbuck EA, Collins AM, Darton T, Dinesh T, Duncan CJA, England A, Faust SN, Ferreira DM, Finn A, Goodman AL, Green CA, Hallis B, Heath PT, Hill H, Horsington BM, Lambe T, Lazarus R, Libri V, Lillie PJ, Mujadidi YF, Payne R, Plested EL, Provstgaard-Morys S, Ramasamy MN, Ramsay M, Read RC, Robinson H, Screaton GR, Singh N, Turner DPJ, Turner PJ, Vichos I, White R, **Nguyen-Van-Tam JS**, Snape MD; Com-COV2 Study Group.  
Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.  
*Lancet*. 2022 Jan 1;399(10319):36-49. doi: 10.1016/S0140-6736(21)02718-5. Epub 2021 Dec 6. Erratum in: *Lancet*. 2022 Feb 26;399(10327):802. PMID: 34883053; PMCID: PMC8648333.
163. Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T, Crook D, Stuart DI, Mongkolsapaya J, **Nguyen-Van-Tam JS**, Snape MD, Screaton GR; Com-COV2 study group.  
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.  
*Lancet*. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20. PMID: 34942101; PMCID: PMC8687667.
164. Närhi F, Moonesinghe SR, Shenkin SD, Drake TM, Mulholland RH, Donegan C, Dunning J, Fairfield CJ, Girvan M, Hardwick HE, Ho A, Leeming G, **Nguyen-Van-Tam JS**, Pius R, Russell CD, Shaw CA, Spencer RG, Turtle L, Openshaw PJM, Baillie JK, Harrison EM, Semple MG, Docherty AB; ISARIC4C investigators. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study.  
*Lancet Digit Health*. 2022 Apr;4(4):e220-e234. doi: 10.1016/S2589-7500(22)00018-8. PMID: 35337642; PMCID: PMC8940185.

165. Killingley B, Mann AJ, Kalinova M, Boyers A, Goonawardane N, Zhou J, Lindsell K, Hare SS, Brown J, Frise R, Smith E, Hopkins C, Noulin N, Löndt B, Wilkinson T, Harden S, McShane H, Baillet M, Gilbert A, Jacobs M, Charman C, Mande P, Nguyen-Van-Tam JS, Semple MG, Read RC, Ferguson NM, Openshaw PJ, Rapeport G, Barclay WS, Catchpole AP, Chiu C.  
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.  
**Nat Med.** 2022 Mar 31. doi: 10.1038/s41591-022-01780-9. Epub ahead of print. PMID: 35361992.
166. Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, Baxter D, Bula M, Cathie K, Chatterjee K, Dejnirattisai W, Dodd K, Enever Y, Qureshi E, Goodman AL, Green CA, Harndahl L, Haughney J, Hicks A, van der Klaauw AA, Kwok J, Libri V, Llewelyn MJ, McGregor AC, Minassian AM, Moore P, Mughal M, Mujadidi YF, Holliday K, Osanlou O, Osanlou R, Owens DR, Pacurar M, Palfreeman A, Pan D, Rampling T, Regan K, Saich S, Serafimova T, Saralaya D, Sreaton GR, Sharma S, Sheridan R, Sturdy A, Supasa P, Thomson EC, Todd S, Twelves C, Read RC, Charlton S, Hallis B, Ramsay M, Andrews N, Lambe T, **Nguyen-Van-Tam JS**, Cornelius V, Snape MD, Faust SN; COV-BOOST study group.  
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.  
**J Infect.** 2022 Apr 9;S0163-4453(22)00200-6. doi: 10.1016/j.jinf.2022.04.018. Epub ahead of print. PMID: 35405168; PMCID: PMC8993491.
167. Swann OV, Pollock L, Holden KA, Munro APS, Bennett A, Williams TC, Turtle L, Fairfield CJ, Drake TM, Faust SN, Sinha IP, Roland D, Whittaker E, Ladhani SN, **Nguyen-Van-Tam JS**, Girvan M, Donohue C, Donegan C, Spencer RG, Hardwick HE, Openshaw PJM, Baillie JK, Harrison EM, Docherty AB, Semple MG; ISARIC4C Investigators.  
Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves.  
**Pediatr Res.** 2022 Apr 22. doi: 10.1038/s41390-022-02052-5. Epub ahead of print. PMID: 35449394.
168. Abhishek A, Boyton RJ, McKnight A, Coates L, Bluett J, Barber VS, Cureton L, Francis A, Appelbe D, Eldridge L, Julier P, Peckham N, Valdes AM, Rombach I, Altmann DM, **Nguyen-Van-Tam J**, Williams HC, Cook JA.  
Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study).  
**BMJ Open.** 2022 May 3;12(5):e062599. doi: 10.1136/bmjopen-2022-062599. PMID: 35504634; PMCID: PMC9066090.

## **EDITORIALS AND REVIEW ARTICLES**

1. **Nguyen-Van-Tam JS**, Neal KR.  
Clinical effectiveness, policies and practices for pneumococcal and influenza vaccines.  
*Semin Resp Infect*, 1999; 14(2); 184-195.
2. **Nguyen-Van-Tam JS**.  
Zanamivir for influenza: a public health perspective.  
*Br Med J*, 1999; 319: 655-656.
3. **Nguyen-Van-Tam JS**, Hampson AW.  
The epidemiology and clinical impact of pandemic influenza.  
*Vaccine*, 2003; 21: 1762-1768.
4. Teo SS, **Nguyen-Van-Tam JS**, Booy R.  
Influenza burden of illness, diagnosis, treatment and prevention: what's the evidence in children and where are the gaps?  
*Arch Dis Child*, 2005; 90: 532-536.
5. **Nguyen-Van-Tam JS**.  
Influenza related hospital admissions in children: evidence about the burden keeps growing but the route to policy change remains uncertain.  
*Arch Dis Child*, 2006; 91(1): 5-7.
6. WHO Writing Group (**listed as J Van-Tam**).  
Nonpharmaceutical interventions for pandemic influenza, international measures.  
*Emerg Infect Dis*, 2006; 12(1): 81-7.
7. WHO Writing Group (**listed as J Van-Tam**).  
Nonpharmaceutical interventions for pandemic influenza, national and community measures.  
*Emerg Infect Dis*, 2006; 12(1): 88-94.
8. Sarangi J, Sellwood C, **Nguyen-Van-Tam JS**. Responding to bird influenza: past, present and future.  
*Travel Med Infect Dis*. 2008 Jul;6(4):190-4. Epub 2008 May 23. PubMed PMID: 18571107.
9. Sellwood C, **Nguyen-Van-Tam JS**.  
Avian influenza and the threat of the next human pandemic.  
*J Hosp Infect*, 2007 ;65 Suppl 2: 10-3.
10. Gupta RK, George R, **Nguyen-Van-Tam JS**.  
Bacterial pneumonia and pandemic influenza planning.  
*Emerg Infect Dis*, 2008 Aug;14(8):1187-92
11. **Nguyen-Van-Tam JS**.  
Oseltamivir for seasonal, avian and pandemic influenza: 10 years of clinical experience.  
*J Antimicrob Chemother*, 2010; 65 Suppl 2:ii3-4. Doi:10.1093/jac/dkq033
12. Killingley B, Enstone J, Booy R, Hayward A, Oxford J, Ferguson N, **Nguyen-Van-Tam J**; Influenza Transmission Strategy Development Group.  
Potential role of human challenge studies for investigation of influenza transmission.  
*Lancet Infect Dis*. 2011 Nov;11(11):879-86. Epub 2011 Jul 26. Review. PubMed PMID: 21798808.

13. Nicoll A, Brown C, Karcher F, Penttinen P, Hegermann-Lindencrone M, Villanueva S, Ciotti M, Jean-Gilles L, Rehm S, **Nguyen-Van-Tam JS**.  
Developing pandemic preparedness in Europe in the 21st century: experience, evolution and next steps.  
*Bull World Health Organ*. 2012 Apr 1;90(4):311-7. PubMed PMID: 22511829; PubMed Central PMCID: PMC3324872.
14. Beck CR, Sokal R, Arunachalam N, Puleston R, Cichowska A, Kessel A, Zambon M, **Nguyen-Van-Tam JS**; UK Antiviral Effectiveness Review Group.  
Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic.  
*Influenza Other Respir Viruses*. 2013 Jan;7 Suppl 1:14-24.doi: 10.1111/irv.12048. Review. PubMed PMID: 23279893.
15. **Nguyen-Van-Tam JS**, Sellwood C.  
Intervention strategies for emerging respiratory virus infections: policy and public health considerations.  
*Curr Opin Virol*. 2013 Apr;3(2):192-8. doi: 10.1016/j.coviro.2013.02.004. Epub 2013 Mar 9. Review. PubMed PMID: 23477831.
16. **Nguyen-Van-Tam JS**, Sellwood C.  
Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines.  
*Expert Rev Vaccines*. 2013 Aug;12(8):825-8. doi: 10.1586/14760584.2013.814832. PubMed PMID: 23984955.
17. Coia JE, Ritchie L, Adishes A, Makison Booth C, Bradley C, Bunyan D, Carson G, Fry C, Hoffman P, Jenkins D, Phin N, Taylor B, **Nguyen-Van-Tam JS**, Zuckerman M; Healthcare Infection Society Working Group on Respiratory and Facial Protection.  
Guidance on the use of respiratory and facial protection equipment.  
*J Hosp Infect*. 2013 Nov;85(3):170-82. doi: 10.1016/j.jhin.2013.06.020. Epub 2013 Sep 17. PubMed PMID: 24051190.
18. Killingley B, **Nguyen-Van-Tam J**.  
Routes of influenza transmission.  
*Influenza and Other Respir Viruses*. 2013 Sep;7 Suppl 2:42-51. doi: 10.1111/irv.12080. PubMed PMID: 24034483.
19. **Nguyen-Van-Tam JS**, Openshaw PJ, Nicholson KG.  
Antivirals for influenza: where now for clinical practice and pandemic preparedness?  
*Lancet*. 2014 Aug 2;384(9941):386-7. doi: 10.1016/S0140-6736(14)60726-1. Epub 2014 May 14. PubMed PMID: 24837882.
20. Wiysonge CS, Adeniyi FB, Shindo N, Briand S, **Nguyen-Van-Tam JS**, Nicholson KG, Leibovici L, Paul M.  
Cochrane column.  
*Int J Epidemiol*. 2014 Dec;43(6):1691-6. doi: 10.1093/ije/dyu219. Epub 2014 Nov 20. PubMed PMID: 25413996.
21. **Nguyen-Van-Tam JS**, Venkatesan S, Muthuri SG, Myles PR.  
Neuraminidase inhibitors: who, when, where?  
*Clin Microbiol Infect*. 2015 Mar;21(3):222-225. doi: 10.1016/j.cmi.2014.11.020. Epub 2014 Nov 27. Review. PubMed PMID: 25703253.
22. **Nguyen-Van-Tam JS**.  
Editorial (untitled).  
*Influenza Other Respir Viruses*. 2015 Mar 31. doi: 10.1111/irv.12311. PubMed PMID: 25824028.

23. O'Reilly F, Dolan GP, **Nguyen-Van-Tam J**, Noone P.  
Practical prevention of nosocomial influenza transmission, 'a hierarchical control' issue.  
**Occup Med (Lond)**. 2015 Oct 13. pii: kqv155. [Epub ahead of print] PubMed PMID: 26464479.
24. **Nguyen-Van-Tam J**, Gross D, Sturkenboom M, Parrish-Sprowl J.  
Influenza vaccines really work? Keeping apart the true from the false.  
**Vaccine**. 2015 Aug 28. pii: S0264-410X(15)01180-9. doi: 0.1016/j.vaccine.2015.08.052. [Epub ahead of print] PubMed PMID: 26319065.
25. Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, Al-Omari A, Hajeer AH, Senga M, Denison MR, **Nguyen-Van-Tam JS**, Shindo N, Bermingham A, nChappell JD, Van Kerkhove MD, Fowler RA.  
Special Report: Middle East Respiratory Syndrome.  
**N Engl J Med**. 2017 Feb 9;376(6):584-594. doi: 10.1056/NEJMsrl408795. PubMed PMID: 28177862.

## **RESEARCH LETTERS IN SCIENTIFIC JOURNALS**

1. Baker DM, **Nguyen-Van-Tam JS**.  
BCG vaccine and leprosy.  
*Lancet*, 1992; 339: 1236.
2. **Nguyen-Van-Tam JS**, Baker DM.  
Does the patient know best?  
*Br Med J*, 1992; 305: 583.
3. Baker DM, **Nguyen-Van-Tam JS**.  
Non-steroidal anti-inflammatory drugs and appendicitis in patients aged over 50 years.  
*Br J Surg*, 1993; 80(4): 537.
4. **Nguyen-Van-Tam JS**, Baker DM, Pearson JCG.  
Vasectomy and prostate cancer: public health implications.  
*Lancet*, 1993; 341: 1350.
5. **Nguyen-Van-Tam JS**, Warren S, Pearson JCG.  
Uptake of influenza vaccine.  
*Br Med J*, 1994; 309: 126.
6. Ahmed AH, Nicholson KG, **Nguyen-Van-Tam JS**.  
Is there a synergistic effect between previous and current vaccination against influenza?  
*Lancet*, 1995; 346:1556.
7. **Nguyen-Van-Tam JS**, Madeley RJ.  
Vietnamese people in study may have had language difficulties.  
*Br Med J*, 1996; 313: 48.
8. **Nguyen-Van-Tam JS**, Kyaw MH, Pearson JCG.  
Age is not only criterion for flu vaccine.  
*Br Med J*, 1998; 317: 946-947.
9. Twelves C, Hargreaves D, **Nguyen-Van-Tam J**, Ng T.  
Capecitabine monotherapy in metastatic colorectal cancer.  
*Lancet Oncology*, 2001; 2(7): 400.
10. Johnson AP, Warner M, **Nguyen-Van-Tam JS**, Livermore DM.  
Activity of gemifloxacin against invasive and multi-resistant *Streptococcus pneumoniae* isolates collected in the UK.  
*J Antimicrob Chemoth*, 2003; 51(1): 188-190.
11. Gupta RK, **Nguyen-Van-Tam JS**.  
Oseltamivir resistance in influenza A (H5N1) infection.  
*N Engl J Med*, 2006; 354(13): 1423-4.
12. McMenamin J, Phin N, Smyth B, Couzens Z, **Nguyen-Van-Tam JS**. Minimum dataset for confirmed human cases of influenza H5N1.  
*Lancet*. 2008 Dec 13;372(9655):2022.
13. **Nguyen-Van-Tam JS**, Nicholson KG.  
Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.  
*J Clin Virol*, 2011 Feb;50(2):183. Epub 2010 Nov 26. PubMed PMID: 21112812.
12. Rashid H, Booy R, Heron L, Memish ZA, **Nguyen-Van-Tam J**, Barasheed O, Haworth E. Unmasking masks in Makkah: preventing influenza at Hajj.  
*Clin Infect Dis*. 2012 Jan 1;54(1):151-3. PubMed PMID: 22187415.

13. Dunning J, **Nguyen-Van-Tam J**, Nicholson K, Openshaw P.  
Doctors accepting flu vaccination is the sensible and responsible choice.  
*Br Med J*. 2011 Nov 8;343: d7199. doi: 10.1136/bmj.d7199. PubMed PMID: 22077079.
14. Rashid H, Booy R, Heron L, Memish ZA, **Nguyen-Van-Tam J**, Barasheed O, Haworth E. Unmasking masks in Makkah: preventing influenza at Hajj.  
*Clin Infect Dis*. 2012 Jan 1;54(1):151-3. doi: 10.1093/cid/cir826. PubMed PMID: 22187415
15. **Nguyen-Van-Tam JS**.  
Principal author of PRIDE study responds to news story in The BMJ claiming that the study was based on "flawed" analysis.  
*BMJ*. 2014 Apr 29;348:g2935. doi: 10.1136/bmj.g2935. PubMed PMID: 24780605
16. Leonardi-Bee J, Venkatesan S, Muthuri SG, **Nguyen-Van-Tam JS**, Myles PR; PRIDE research consortium. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.  
*Lancet Respir Med*. 2014 Jul;2(7):e10-2. doi: 10.1016/S2213-2600(14)70137-7. Epub 2014 Jun 16. PMID: 24948433.
17. **Nguyen-Van-Tam JS**, Openshaw PJ, Nicholson KG.  
Neuraminidase inhibitors for influenza complications--Authors' reply.  
*Lancet*. 2014 Oct 4;384(9950):1261-2. doi: 10.1016/S0140-6736(14)61762-1. PubMed PMID: 25283566.
18. Beyer WE, McElhaney J, Smith DJ, Monto AS, **Nguyen-Van-Tam JS**, Osterhaus AD.  
Reply: Letter to the editor, Cochrane rearranged.  
*Vaccine*. 2015 Jan 1;33(1):13-4. doi: 10.1016/j.vaccine.2014.05.045. Epub 2014 May 20. PubMed PMID: 24852718.
19. Venkatesan S, Myles PR, Memish Z, **Nguyen-Van-Tam JS**. Reply to Jones et al.  
*Clin Infect Dis*. 2017 Sep 15;65(6):1051. doi: 10.1093/cid/cix427. PubMed PMID: 28505297.
20. Shaw RH, Stuart A, Greenland M, Liu X, **Nguyen Van-Tam JS**, Snape MD; Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data.  
*Lancet*. 2021 May 29;397(10289):2043-2046. doi: 10.1016/S0140-6736(21)01115-6. Epub 2021 May 12. Erratum in: *Lancet*. 2021 May 18;: PMID: 33991480; PMCID: PMC8115940.

*\*I do not record Abstracts of plenary lectures, oral papers and posters presented at Scientific Symposia and Conferences, because these are very numerous and do not add value over and above my formal publication record.*

## **CHAPTERS IN TEXTBOOKS**

1. **Nguyen-Van-Tam JS** and Logan RFA.  
*Gastrointestinal Disease* in: Charlton J and Murphy M (Eds).  
Health of Adult Britain 1841-1991. Decennial Supplement No.13, Vol.2.  
London: Office for National Statistics, 1997. pp 129-39.
2. **Nguyen-Van-Tam JS**.  
*Influenza epidemiology* in: Nicholson KG, Webster RG, Hay AJ (Eds). Textbook of Influenza.  
London: Blackwell Science Publishers, 1998. pp 181-206.
3. **Nguyen-Van-Tam JS**.  
*Epidemic and pandemic influenza* in: Ayres JG, Harrison RM, Nichols GL, Maynard RL (Eds).  
Environmental Medicine.  
London: Hodder Arnold, 2010. pp 213-224.
4. **Nguyen-Van-Tam JS**.  
*Respiratory virus infections* in: Lim WS (Ed). Oxford Pocket Book of Respiratory Medicine. Oxford: OUP,  
2012 (in press).
5. **Nguyen-Van-Tam JS** and Bresee J.  
*Pandemic preparedness and response* in: Webster RG, Monto AS, Braciale TJ, Lamb RA (Eds). Textbook of  
Influenza, Second Edition.  
Chichester: Wiley Blackwell, 2013. pp 453-469.
1. **Nguyen-Van-Tam JS** and Penttinen P.  
*Preparedness and response to pandemics and other infectious disease emergencies* in: Sellwood C, Wapling A  
(Eds). Health Emergency Preparedness and Response.  
Wallingford: CABI International, 2016.
7. Venkatesan S, Cox RJ, **Nguyen-Van-Tam JS**, Myles PR. *Interpandemic (seasonal) influenza*. European  
Respiratory Society Monograph. London: European Respiratory Society, 2016.
8. **Nguyen-Van-Tam JS** and Rooney K. *Viral pneumonia* in: English W, Ashton-Cleary D (Eds). Recent  
Advances in Critical Care. JP Medical Publishing, 2016

**BOOKS (including Editorships) AND OFFICIAL REPORTS**

1. Fleming DM, Elliot AJ, **Nguyen-Van-Tam JS**, Watson JM, Wise R.  
A winter's tale: coming to terms with winter respiratory illnesses.  
London: Health Protection Agency, 2005.
2. **Nguyen-Van-Tam JS** et al. Technical Report: Expert Advisory Group on Human H5N1 Vaccines.  
Scientific Questions, Stockholm, August 2007. Stockholm: ECDC, 2007.
3. **Van-Tam J**, Sellwood C (Eds). Introduction to Pandemic Influenza. Wallingford: CAB International, 2010.  
ISBN: 978 1 84593 625 9.
4. **Van-Tam J**, Sellwood C (Eds). Pandemic Influenza, 2<sup>nd</sup> Ed. Wallingford: CAB International, 2012.

## **GRANTS HELD/AWARDED SINCE 2000**

1. EU Commission (DG SANCO). 2004-2006. European Pandemic Influenza Exercise (Exercise Common Ground). Co-applicant (1 of 4): **€350,000**.
2. Medical Research Council. 2006. Flu watch:Community study of behavioral & biological determinants of transmission to inform seasonal & pandemic planning. Co-applicant (1 of 6): **£1.26M**.
3. HPA Pump Priming Fund 2006, Title of proposal: Do statins reduce the risk of influenza and acute respiratory infections? A retrospective cohort study. Principal applicant: **£10,000**.
4. HPA Pump Priming Fund 2006, Title of proposal: Development and testing of an apparatus to measure microbial aerosol produced by infectious patients. Co-applicant (1 of 4): **£10,000**.
5. HPA R&D Fund: Studies on influenza virus survival on communal surfaces. Principal Applicant: **£224,000**.
6. UK Clinical Research Collaboration (UKCRC). 2007. Influenza Transmission Strategy Development Group. Principal Applicant: **£59,000**
7. HPA Pump Priming Fund 2007, On the Buses: is public transport a risk factor for the acquisition of influenza? Principal Applicant: **£10,000**
8. Medical Research Council, 2008, Clinical Research Fellowship. Principal Applicant: **£210,000**
9. Department of Health. Influenza transmission human challenge study: Principal Applicant: **£275,000**
10. Medical Research Council/Wellcome Trust, 2009, FluWatch (pandemic extension). Co-applicant: **£3M approx.**
11. Wellcome Trust, 2009, MOSAIC (pandemic influenza). Co-applicant: **£3M approx.**
12. NIHR, 2009. Influenza virus shedding and environmental deposition. Principal Applicant: **£224,000**
13. NIHR, 2009. Vertical transmission of maternal antibody in women vaccinated against swine flu (MUMMYFLU). Principal Applicant **£120,000**
14. NIHR, 2009. Influenza vaccine A/H1N1 head-to-head comparison in adults. Co-Applicant: **£500,000 approx.**
15. World Health Organisation, 2010: Evaluation of the response to pandemic influenza A/H1N1. Principal Applicant: **\$120,000** (Year 1).
16. Department of Health 2009. Influenza Clinical Information Network (FLU-CIN). Principal Applicant: **£210,000**
17. ESRC/MRC PhD studentship. Principal Applicant: **£52,000**
18. F. Hoffmann-La Roche. PRIDE: Post-pandemic Review of anti-Influenza Drug Effectiveness Principal Applicant: **£284,000**.
19. US CDC. EMIT: Evaluating Modes of Influenza Transmission. Principal Applicant: **\$10,800,000**.
20. GlaxoSmithKline: PhD studentship. Principal Applicant: **£159,000**.
21. F. Hoffmann-La Roche. PRIDE: Post-pandemic Review of anti-Influenza Drug Effectiveness – Extension Grant. Principal Applicant: **£169,000**.

22. EU commission (FP7): Pandhub A toolkit for pandemic preparedness at transportation hubs. Co-Applicant: **€3,500,000** (approx)
23. GlaxoSmithKline: Systematic review and meta-analysis of influenza A(H1N1)pdm09 vaccine effectiveness. Principal Applicant: **£100,000**.
24. F. Hoffmann-La Roche. PRIDE: Post-pandemic Review of anti-Influenza Drug Effectiveness – Extension Grant. Principal Applicant: **£102,000**.
25. Versus Arthritis Research Council, UK. Influenza vaccine safety and effectiveness in patients with rheumatic disorders. Co—applicant: **£100,000**
26. NIHR, 2021: Influenza and pneumococcal vaccination in adults with common inflammatory conditions treated with immune suppressing drugs: a study of vaccine uptake, clinical effectiveness, vaccine safety, and facilitators and barriers to vaccination. Co-applicant: **£149,948**
27. NIHR, 2022: Covid-19 vaccination in inflammatory conditions treated with immune suppressing drugs: a study of clinical effectiveness and vaccine safety using data from the Clinical Practice Research Datalink (CPRD). Co-applicant: **£149,979**
28. NIHR/MRC, 2021: Covid-19 vaccination in inflammatory conditions treated with immune suppressing drugs: a study of clinical effectiveness and vaccine safety using data from the Clinical Practice Research Datalink (CPRD). Co-applicant: **£914,561**
29. NIHR, 2022: COVID-19 vaccination in adults with inflammatory conditions treated with immune suppressing drugs: a study of clinical effectiveness and vaccine safety, using data from the CPRD. Co-applicant: **£142,754**.

## **NON-ACADEMIC APPOINTMENTS**

1988-2000	Commissioned into Royal Army Medical Corps (V) Army Number 530726
1993	Promoted to rank of Major, RAMC(V)
1988-93	Medical Officer, Donnington Park Motor Racing Circuit
*2022	Honorary Colonel (designate), see below.

In the Territorial Army I was posted to Lincolnshire ACF as Regimental Medical Officer. In addition to conducting routine medical examinations, my responsibilities included a managerial function at County Headquarters advising my commanding officer and his permanent staff officers on any medical or environmental matter, which held implications for the unit. At annual camps my duties involved providing medical care for all personnel, including 24-hour accident and emergency cover. This involved commanding a small staff including drivers, medical technicians, and nursing officers. In addition, I held a secondary position as an adventurous training instructor (Joint Services Mountain Expedition Leader). In this capacity I was the officer-in-command of a springtime adventurous training camp every year from 1989 to 1997.

Every year in June, I led a team of three in the Cheviot 2000 Fell Race; this competition is exclusive to the Police and Armed Forces and involves covering 26 miles over 11 peaks (each one over 2000 ft.), carrying equipment. In the Officer's Mess I was wines member, and over the years acted as escorting officer to many visiting dignitaries. I greatly enjoyed my military duties, and believe they have given me self-motivation, a strong sense of 'team spirit', and considerable experience in person management, negotiation, diplomacy, delegation and effective communication with people from many different backgrounds. In 1997 I was awarded a military MBE.

Having completed 12 years' service, I resigned my commission in July 2000 because of career and family pressures. However, I stayed on as a Civilian Assistant (Adventurous Training) to the Cadet Forces until late 2005. My latter 'exploits' included the completion of a 150km high mountain traverse through the French Alps in July 2003, as one of three British Army mountaineering instructors, and ascent of Mt. Kilimanjaro in October 2005 and Mt. Fuji in 2014.

I am designated to be Honorary Colonel, 306 Hospital Support Regiment, Royal Army Medical Corps, commencing July 2022.

## **OTHER QUALIFICATIONS**

1980	Glider pilot (via Royal Air Force, expired)
1988	Joint Services Unit Expedition Leader (UEL)
1989	Joint Services Mountain Expedition Leader (JS MEL)
1992	British Army Smallbore Range Officer Authorization (expired)
1996	European Resuscitation Council: Advanced Cardiac Life Support (ACLS) Provider (expired)
2018	Basic Life Support and use of automated cardiac defibrillator
2021	Covid-19 Vaccinator Training

**OUTSIDE INTERESTS**

**NOT RELEVANT**